AWARD NUMBER: W81XWH-11-1-0491

TITLE: Role of microRNA in aggressive prostate cancer

PRINCIPAL INVESTIGATOR: Hsieh, Jer-Tsong

CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center
Dallas, TX 75390

REPORT DATE: September 2015

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
### Role of microRNA in aggressive prostate cancer

The majority of mortality of prostate cancer (PCa) is due to the recurrent metastasized castration resistance PCa. The acquisition of epithelial–to-mesenchymal transition (EMT) in PCa signifies the initial process of cancer metastasis. Our previous findings unveiled that DAB2IP is down-regulated in high-grade PCa specimens and this novel tumor suppressor can block EMT leading to lymph node metastasis. It has recently been associated with the onset of cancer stem cell (CSC) that is considered as cancer initiating cell with a survival advantage during the course of cancer therapy. However, the mechanism of action is not fully characterized. Using microRNA microarray screening, we found microRNA-363 (miR363) is significantly down regulated in several DAB2IP knockdown (KD) prostate cells. In particular, miR363 is predominately expressed in normal prostate and belongs to the miR106a-363 cluster that is closely resembled to the oncogenic miR17-92 cluster in their seed sequence. It appears that DAB2IP significantly regulates the expression of a unique miR-363; the profile of miR-363 expression appears to be highly specific in normal prostate. The objective of this project is to delineate the functional links of miR-363 with the appearance of CSC and its clinical correlation in aggressive PCa.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>1</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>2</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>2</td>
</tr>
<tr>
<td>4. Impact</td>
<td>3</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>4</td>
</tr>
<tr>
<td>6. Products</td>
<td>4</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>4</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>4</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>5</td>
</tr>
</tbody>
</table>
INTRODUCTION

MicroRNA (miR) is a large family of a short sequence of single-stranded noncoding RNAs and known to regulate approximately 60% of protein-coding genes by post-transcriptional suppression, target mRNA degradation, or translational inhibition (1, 2). Until now, many miRs have been identified to be associated with different stages of tumor development. Based on their seed sequence of 2-7 nucleotides are grouped into different family for predicting the potential target gene(s), the function of miRs could be divided into onco-miR and tumor suppressor miR. However, only handful of them has been demonstrated experimentally (Appendix: Review Article).

In general, similar to most protein-coding genes, miRNA genes can be regulated at transcriptional or post-transcriptional level (3). Unlike most eukaryotic protein genes, several miRNAs such as miR-106a-363 (4) and miR-17-92 are clustered together to generate a polycistronic primary transcript (5-7), which further complicates the regulatory scheme of miRNA biogenesis because each individual miRNA derived from one cluster may have different functional roles as well as expression levels in any given cell or tissue. For example, miR-363 belongs to the polycistronic miR-106a-363 cluster containing six miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363), located on chromosome X. Unlike the other five miRNAs with similar seed sequences and similar functions as the oncogenic miR-17-92 cluster (8), we demonstrated that miR-363 is a tumor suppressor miRNA capable of suppressing epithelial-to-mesenchymal transition (EMT) in prostate cancer (PCa).

In this project, we unveiled a new post-transcriptional regulatory machinery of miR turnover by a novel protein complex- Interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) (9, 10) and exoribonuclease XRN1. This machinery is very specific to miR-363 but not other member miRNAs in miR-106a-363 cluster. Also, elevated IFIT5 is correlated with PCa tumor grade. In addition, IFIT5 complex can regulate the turnover of other tumor suppressor miRNAs, particularly, involved in regulating cancer stem cell.

Taken together, IFIT5-XRN1 complex mediates a specific degradation of tumor suppressor miRNA from its cluster, which could provide a new understanding of miRNA biogenesis. IFIT5 also represents a potential target for metastatic PCa.

REFERENCES


KEYWORDS
Prostate cancer, metastasis, epithelial-to-mesenchymal transition, cancer stem cell, microRNA-363, microRNA turnover, Interferon-induced protein with tetratricopeptide repeats 5 (IFIT5), exoribonuclease XRN1

ACCOMPLISHMENTS
A. PROJECT ACCOMPLISHMENTS

Goal 1: Study the regulation of miR-363 gene expression by DAB2IP.
- IFIT5-XRN1 complex represents unique machinery for miR-363 turnover (Appendix: Figure 1 and Manuscript draft).
- IFIT5 complex can specifically degrade mature miR-363 from miR-106a-363 cluster in PCa cells (Appendix: Manuscript draft-Figure 1-3, and Additional file 1-2).
- DAB2IP regulates the expression of IFIT5-XRN1 protein complex (Appendix: Manuscript draft-Figure 2 and 4)

Goal 2: Delineate the functional role of miR-363 in modulating Cancer Stem cell (CSC) phenotype.
- IFIT5-XRN1 complex specifically modulates the turnover of miRNAs with 5’-overhanging sequence (Appendix: Manuscript draft-Figure 3-5, and Additional file 3-5).
- MiR-363 can inhibit EMT leading to PCa metastases by targeting Slug mRNA (Appendix: Manuscript draft-Figure 5-7 and Additional file 6).
- IFIT5 complex also degrades miR-101, miR-128, miR-203, and miR-345 that are targeting Bmi-1 mRNA associated with CSC (Appendix: Figure 2, 4 and 5).

Goal 3: Study the correlation of DAB2IP and miR-363 in PCa progression.
- Loss of miR-363 expression is correlated with clinical PCa development mRNA (Appendix: Manuscript draft-Figure 8 and Additional file 8).
- Increased IFIT5 expression is correlated with clinical PCa development (Appendix: Manuscript draft-Figure 8 and Additional file 8).
- A positive correlation between IFIT5 and XRN1 expression is detected in PCa specimens (Appendix: Manuscript draft-Additional file 8)

B. OTHER ACHIEVEMENTS
• IFIT5 complex also degrades miR-101, miR-128, miR-203, and miR-345 that are targeting Bmi-1 mRNA in Glioblastoma (GBM) cells (Appendix: Figure 2 and 4).
• A positive correlation between IFIT5 and Bmi-1 expression was observed in clinical GBM database (Appendix: Figure 4).
• IFIT5 is able to increase stemness phenotype of PCa via Bmi-1-mediated pathway (Appendix: Figure 5).
• Dr. Lo has received a 2-years postdoctoral training award from DOD-PCRP in 2014.

IMPACT
MiRNA is initially transcribed into a long primary transcript (pri-miRNA) and subsequently processed by Drosha and Dicer-mediated endonuclease cleavage to generate mature miRNA. The miRNA biogenesis becomes more complicated when differential expression of individual miRNA located in the same polycistronic cluster is observed. In this project, we identify the tumor suppressive effect of miR-363, from a cluster that contains the rest of miRNAs characterized as onco-miRs, on intervening the EMT process in PCa cells. Most significantly, a new miRNA degradation machinery associated with IFIT5 that specifically recognizes a unique 5’-end structure of miRNA and recruits exoribonuclease (XRN1) to degrade this miRNA is identified (Appendix: Figure 1) from this project, which could provide a new aspect of miRNA biogenesis for the regulation of other tumor suppressor miRNA genes as well.

Despite of completing 3 specific aims proposed in original project, we extended our effort to discover the specificity of IFIT5 in modulating miRNA biogenesis. In addition to PCa, we also found IFIT5 elevation in GBM cells. Therefore, we profile miRNA expression in both PCa and GBM cells by manipulating IFIT5 levels. Indeed, the majority of miRNA modulated by IFIT3 contain the 5’-overhanging sequence (Appendix: Figure 2). Among that, we found 4 different miRNAs (101, 128, 203, 345) consistently decreased in the presence of IFIT5 from all the PCa and GBM cells examined in this experiment (Appendix: Figure 3A) and validated by additional PCa and GBM cells (Appendix: Figure 4). Interestingly, all these miRs appear to target Bmi-1 (Appendix: Figure 3A) that is involved in stem cell formation. From TCGA database, we also observed a significant correlation between IFTI5 and Bmi-1 expression (Appendix: Figure 3B). Furthermore, data from prostasphere formation study using PCa cells concluded that the presence of IFIT5 is critical for increasing stemness phenotype in PCa in which Bmi-1 is a key downstream factor (Appendix: Figure 5). Taken together, the overall project discovers a new regulation of microRNA biogenesis that is related with PCa progression.

Interferon-induced tetratricopeptide repeat (IFIT) protein family is first identified as viral RNAs biding protein that is a part of antiviral defense mechanisms by reducing virus replication or disrupt protein–protein interactions in host translation-initiation machinery. Among IFIT orthologs, IFIT1, IFIT2 and IFIT3 form a complex through its tetratricopeptide repeats (TPR). On the contrary, IFIT5 acts solely as a monomer and binds directly to RNA molecules via its convoluted RNA-binding cleft. In addition, IFIT5
has been shown to directly bind to endogenous cellular RNA with a 5’-end phosphate cap, including transfer RNA (tRNA), which partially shared a structural similarity with the precursor form of small RNAs such as small hairpin RNA (shRNA) and miRs. We have demonstrated the first time that IFIT5 is able to specifically recognize a unique structure in the precursor miR-363 and recruit XRN1 to degrade miR363. We have also shown that the significant elevation of IFIT5 is detected in several PCa cells undergone EMT leading to highly metastatic potential and the expression level of IFIT5 is correlated with that of miR-363 in PCa specimens.

Furthermore, IFIT5 is also elevated in GBM. Using both PCa and GBM cell models to profile IFIT5-mediated miRs, a subset of miRs (101, 128, 203, 345) is identified and shares a common target Bmi-1 mRNA that is involved in stem cell development. Indeed, the presence of IFIT5 can elicit CSC phenotype that is correlated with Bmi-1 expression. Overall, this study unveils a new mechanism of miRNA degradation, particularly, tumor suppressor miR involved in EMT and CSC. Most significantly, this is the first study to unveil this miRNA turnover machinery in PCa research community. There are several major impact: developing new reagents for the area of miRNA research, identifying new prognostic marker for PCa patients, unveiling new function of IFIT5, training postdoctor to become independent investigator, and expanding new research horizon to other diseases.

**CHANGES/PROBLEMS**

N/A

**PRODUCTS**

Publications, Conference papers, and Presentations


**PARTICIPANTS AND OTHER COLLABORATING ORGANIZATIONS**

N/A

**SPECIAL REPORTING REQUIREMENTS**
Figure 1 Schematic representation of IFIT5-mediated pre-miR-363 turnover leading to EMT.
Figure 2 Profiling miR mediated by IFIT5 degradation complex from PCa and GBM cells. Small RNA was prepared from PCa or GBM cells by either knocking down endogenous IFIT5 or overexpressing IFIT5 and subjected to microRNA microarray. By comparing each set, the miR candidates were chosen and their secondary structure were deduced. Based on the 5’-sequences of each miRNA was divided into SN (single-nucleotide overhanging), MN (multiple-nucleotides overhanging), and DS: double-stranded overhanging.

<table>
<thead>
<tr>
<th>5’ end</th>
<th># out of 40</th>
<th>percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>SN</td>
<td>20/40</td>
<td>50.0%</td>
</tr>
<tr>
<td>MN</td>
<td>7/40</td>
<td>17.5%</td>
</tr>
<tr>
<td>DS</td>
<td>13/40</td>
<td>32.5%</td>
</tr>
</tbody>
</table>

miR-146a: SN-C
miR-203: SN-G
miR-193: SN-C
miR-335: SN-U
miR-125b: SN-U
miR-15a: DS
miR-101: SN-U
miR-200a: SN-C
miR-128: SN-U
miR-130a: SN-U
miR-184: SN-C

<table>
<thead>
<tr>
<th>5’END</th>
<th># out of 21</th>
<th>percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>SN</td>
<td>12/31</td>
<td>38.7%</td>
</tr>
<tr>
<td>MN</td>
<td>5/31</td>
<td>16.1%</td>
</tr>
<tr>
<td>DS</td>
<td>11/31</td>
<td>33.3%</td>
</tr>
<tr>
<td>None</td>
<td>3/31</td>
<td>9.5%</td>
</tr>
</tbody>
</table>

miR-202: SN-G
miR-125b: SN-U
miR-128: SN-U
miR-183: ON

<table>
<thead>
<tr>
<th>5’END</th>
<th># out of 30</th>
<th>percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>SN</td>
<td>15/30</td>
<td>50%</td>
</tr>
<tr>
<td>MN</td>
<td>6/30</td>
<td>20%</td>
</tr>
<tr>
<td>DS</td>
<td>6/30</td>
<td>20%</td>
</tr>
<tr>
<td>None</td>
<td>1/30</td>
<td>3.3%</td>
</tr>
</tbody>
</table>

miR-125b: SN-U
miR-335: SN-U
miR-130a: SN-U
miR-203: SN-G
miR-200a: SN-C
miR-128: SN-U
miR-183: ON

*SN: single-nucleotide overhanging
*MN: multiple-nucleotides overhanging
*DS: double-stranded overhanging
Figure 3 Bmi-1 as a common target and its clinical correlation between IFIT5 expression in PCa and GBM. (A) Identification of common miRs in PCa and GBM cells modulated by IFIT5 and their potential target mRNA (B) Clinical correlation between IFIT5 and Bmi-1 in clinical PCa and brain cancer.
Figure 4 Validation of miRNA expression modulated by IFIT5 in PCa and GBM cells. By knocking down endogenous IFIT5 expression in several PCa cell lines, the expression level of Bmi-1 and Sox4 proteins were determined by western blot analyses. These cells were also subjected to ultralow attachment plate for their sphere formation.
Figure 5 The role of IFIT5 in prostasphere formation of PCa cells. By modulating IFIT5 expression in several PCa and GBM cell lines by transfecting either cDNA for increasing protein expression or specific shRNA for decreasing protein expression, the expression level of each candidate miRNAs was determined using quantitative real-time reverse transcription polymerase chain reaction.
The role of microRNAs in prostate cancer progression

U-Ging Lo, Diane Yang, Jer-Tsong Hsieh

Departments of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Corresponding to: Jer-Tsong Hsieh. 5323 Harry Hines Blvd. Dallas, TX 75390, USA. Email: JT.Hsieh@UTSouthwestern.edu.

Abstract: Prostate cancer (PCa) is the most common male malignancy and the second highest cause of cancer-related mortality in United States. MicroRNAs (miRNAs) are small non-coding RNAs that represent a new mechanism to regulate mRNA post-transcriptionally. It is involved in diverse physiological and pathophysiological process. Dysregulation of miRNAs has been associated with the multistep progression of PCa from prostatic intraepithelial neoplasia (PIN), localized adenocarcinoma to metastatic castration-resistance PCa (CRPC). Identification of unique miRNA could provide new biomarkers for PCa and develop into therapeutic strategies. In this review, we will summarize a broad spectrum of both tumor suppressive and oncogenic miRNAs, and their mechanisms contribute to prostate carcinogenesis.

Key Words: Androgen receptor (AR); castration-resistant prostate cancer (CRPC); epithelial-to-mesenchymal transition (EMT); microRNA (miRNA)

Submitted Aug 01, 2013. Accepted for publication Aug 05, 2013.
doi: 10.3978/j.issn.2223-4683.2013.08.01
Scan to your mobile device or view this article at: http://www.amepc.org/tau/article/view/2550/3635

Introduction

Prostate cancer (PCa) is a typical hormone-dependent disease (1); however, almost all PCa patients with androgen-ablation therapy ultimately become castration-resistant prostate cancer (CRPC), which contributes to the majority of mortality in PCa. Androgen receptor (AR) is known as a key mitogen for the growth and morphogen for the development of prostate. In PCa, AR activity is critical for the disease progression and becomes hyperactivated in CRPC. Mounting evidences indicate that the development of PCa is highly associated with aberrant AR activity resulted from AR gene amplification and/or mutation, alternative splicing (2-7), the cross talk with growth factor signaling pathways (8-13), and the presence of AR co-activators and AR co-repressors (14-17). In particular, Dicer-mediated maturation of microRNAs (miRNAs) suppresses the expression level of AR co-repressors, NCoR and SMRT, leading to enhance AR transcriptional activity (18). Based on the interaction between Dicer and AR, the correlation between AR and microRNA signaling has been broadly examined to investigate the fundamental role of miRNAs in PCa progression.

miRNAs are a large family of small 20-25 nt single stranded noncoding RNAs, which can interfere with the expression of ~60% protein coding genes by post-transcriptional suppression, target mRNA degradation, or translational inhibition (19). In the past two decades, significant advances have been achieved in miRNA research. miRNAs are found to be highly conserved among the animal phylogeny. Based on their conserved sequences, miRNAs shared an identical seed region of 2-7 nucleotides are grouped into different family. Up to date, 63 miRNA families have been categorized and more than 1,000 miRNAs have been fully characterized in their expression, epigenetic regulation, biogenesis and functions. In general, miRNAs are either derived from non-coding RNA transcripts or located within the introns of protein-coding genes (20,21). Multiple miRNAs can be clustered in close proximity and encoded together as a single polycistronic primary transcript, such as miR-106a-363 (22) and miR-17-92 clusters (23). The transcriptional mechanism of microRNA is similar to that of mRNA, miRNA gene promoters are regulated by transcriptional factors that also regulate protein-coding gene expression. For example, the promoter region of miR-21 can be regulated by AR, activation protein 1 (AP-1) and
signal transducer and activator of transcription 3 (STAT-3) (24, 25). Hence elevation of miR-21 in cancer is partially due to aberrant activation of AR and AP-1. Meanwhile, c-Myc is a well-known oncogene that is suggested to regulate an oncogenic miR-17-92 cluster. Overexpression of both c-Myc and miR-17-92 cluster is indicated to enhance the tumor aggressiveness (26). Moreover, the genomic organization of miRNAs reveals that about 52% of miRNA genes are localized at the fragile chromosomal regions, which are susceptible to amplification, deletion and translocation associated with cancer. A recent study indicates that let-7 miRNAs family is located in the genomic regions that are frequently deleted in multiple cancer types including PCa (27). Moreover, the miR-15a/miR-16-1 cluster is located at chromosome 13q14. The frequency of allelic loss at 13q increases from early, advanced to metastatic PCa (28). In addition, aberrant DNA hypermethylation at the CpG island is often observed in the promoter region or transcriptional start site of tumor suppressive miRNAs such as miR-200/-141, miR-205, miR-34, miR-143 and miR-145 associated with PCa (29-32). Thus epigenetic regulation is also a key regulatory mechanism for miRNA gene expression.

In addition to the regulation of miRNA gene expression, the biosynthetic process of miRNA maturation becomes an emerging area. The biogenesis of miRNAs composes sequential steps of RNase III-mediated endonucleolytic cleavage mechanisms (33, 34). In brief, the primary transcripts of miRNAs are transcribed by RNA polymerase II and processed in the nucleus by Drosha and Pasha (DGCR8) into a 70-100 nucleotides-long precursor miRNAs (pre-miRNAs) (35). Pre-miRNAs are exported to the cytoplasm through Exportin 5 and further processed by Dicer, generating a 20-25 nt RNA duplex comprise of a matured guide strand and a complementary passenger strand (miRNA*). The single stranded matured miRNA is then incorporated into the RNA-induced silencing complex (RISC) associated with Agonaut (AGO2), and bound to the complementary sequence on the 3’ untranslated region (3’ UTR) of target mRNA, leading to mRNA degradation (36-38). Based on their post-transcriptional regulation on a variety of target genes, miRNA is expected to be involved in virtually every biologic process in cell. In cancer, based on their post-transcriptional repression on a variety of oncogenes or tumor suppressor genes, miRNAs are also divided into onco-miRNAs (oncomirs) and tumor suppressors miRNAs (Figure 1). Overall, the importance of microRNAs has become a key to gain more understanding of molecular mechanisms associated with prostatic carcinogenesis. In this review, we will focus on key unique miRNAs (Tables 1, 2) involved in PCa.

### Tumor suppressive miRNAs

#### Let-7 family

The let-7 gene encodes a highly conserved miRNA family of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i and miR-98, which are significantly down-regulated in localized PCa, compared to adjacent benign tissues (39). The functionality of let-7 has been shown to target oncogenes involved in cell-cycle regulation, cell migration, proliferation, differentiation, and epithelial-mesenchymal transition (EMT) progression. In particular, let-7g can inhibit tumor growth via post-transcriptional suppression on RAS oncogene (44). On the other hand, loss of let-7 miRNAs is corresponded with elevated level of Enhancer of Zeste homolog 2 (Ezh2) correlated with PCa progression (45). Ectopic expression of let-7 results in the reduction of Ezh2, accompanied with diminished clonogenic ability and sphere formation in PCa cells (45).

Another let-7 target gene is High-mobility group AT-hook 2 (HMGA2) (89) that is highly expressed in PCa compared to adjacent benign tissues. Indeed, HMGA2 was found de-repressed upon let-7 inhibition (43). Meanwhile, co-regulation of HMGA2 and Smad were found to orchestrate an EMT transcriptional network via targeting the promoter of SNAI1 in human hepatocarcinoma cell line (90). These results suggest a possibility that let-7 could inhibit EMT via targeting HMGA2 during PCa progression. Moreover, another study also imply that let-7 can induce cell cycle arrest and xenograft PCa tumor development by suppressing E2F2 and CCND2, which are found to be the direct target of let-7 (43). Lin-28 is a well-identified post-transcriptional suppressor of precursor let-7 maturation (91, 92); An inverse correlation between lin28 and let-7 is also found in many cancer cell lines including PC3 (93). Based on these observations, lin28-mediated let-7 biogenesis has become an important mechanism to impact tumorigenesis. Conversely, let-7 can target the lin28 mRNA, suggesting that a reciprocal feedback loop exists between let-7 and lin28 (94-97). In addition, c-Myc is found to be a key factor involved in this interaction. c-Myc acts as a transcriptional activator for lin-28 gene expression and c-Myc is also found to be a target gene of let-7 family in multiple cancer types (40, 98, 99). Overall, the orchestrated interaction between lin28, let-7 and c-Myc is a complicated network of gene
regulation, which is often altered in cancer cells (100). Also, let-7c is shown to antagonize AR expression by targeting c-Myc (101). Overexpression of let-7 leads to AR suppression, accompanied with attenuated cell proliferation, clonogenicity and anchorage-independent growth in PCa cells (39,41). Overall, the let-7 miRNA family exerts tumor suppressor characteristics via targeting multiple oncogenes including RAS, HMGA2, Ezh2, Lin28 and c-Myc. Therefore, let-7 could be a potential diagnostic biomarker and further developed into a new therapeutic strategy for PCa.

**miR-143 and miR-145**

Both miR-143 and miR-145 are derived from the same
### Table 1 Tumor suppressive miRNAs in PCa

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Target genes</th>
<th>Function</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Let-7</td>
<td>AR, c-MYC</td>
<td>Suppress cell proliferation, clonogenicity and anchorage-independent growth</td>
<td>(39-41)</td>
</tr>
<tr>
<td></td>
<td>HMG A2</td>
<td>Suppress advanced tumor progression</td>
<td>(42)</td>
</tr>
<tr>
<td></td>
<td>E2F2, CCND2</td>
<td>Induce cell cycle arrest in vitro and suppress tumor development in vivo</td>
<td>(43)</td>
</tr>
<tr>
<td></td>
<td>RAS</td>
<td>Inhibit tumor growth</td>
<td>(44)</td>
</tr>
<tr>
<td></td>
<td>EZH2</td>
<td>Inhibit clonogenicity and sphere formation</td>
<td>(45)</td>
</tr>
<tr>
<td>miR-143</td>
<td>KRAS</td>
<td>Suppress cell proliferation, migration in vitro</td>
<td>(46,47)</td>
</tr>
<tr>
<td></td>
<td>ERK5</td>
<td>Arrest cell proliferation and abrogate tumor growth</td>
<td>(48)</td>
</tr>
<tr>
<td></td>
<td>CD133, CD44, OCT4, KLF4, c-MYC</td>
<td>Suppress tumor sphere formation</td>
<td>(49)</td>
</tr>
<tr>
<td>miR-145</td>
<td>FSCN1</td>
<td>Inhibit cell proliferation, invasion, migration and arrest cell cycle</td>
<td>(50)</td>
</tr>
<tr>
<td></td>
<td>OCT4, SOX2, KLF4</td>
<td>Suppress tumor stemness by inhibiting sphere formation</td>
<td>(51)</td>
</tr>
<tr>
<td>miR-200</td>
<td>ZEB1, ZEB2</td>
<td>Prevent PDGF-D induced EMT</td>
<td>(52)</td>
</tr>
<tr>
<td></td>
<td>SLUG</td>
<td>Inhibit TGF-β induced EMT and suppress mesenchymal differentiation</td>
<td>(53,54)</td>
</tr>
<tr>
<td>miR-203</td>
<td>CKAP2, LASP1, WASF1, BIRC5, ASAP1</td>
<td>Suppress cell proliferation, promote cell apoptosis and inhibit metastasis dissemination</td>
<td>(55)</td>
</tr>
<tr>
<td></td>
<td>RUNX2</td>
<td>Inhibit tumor invasion destined for bone metastasis</td>
<td>(55,56)</td>
</tr>
<tr>
<td></td>
<td>PARK7, BRCA1</td>
<td>Impair cell growth by promoting apoptosis and cell cycle arrest</td>
<td>(57)</td>
</tr>
<tr>
<td></td>
<td>ZEB2, Bmi, Survivin</td>
<td>Suppress bone metastasis via inhibition of cell motility, invasion and EMT</td>
<td>(58)</td>
</tr>
<tr>
<td>miR-205</td>
<td>ErbB3, E2F1, E2F5, PKCε, BCL2, PSAP, ARA24, HRAS, PARK7, AR, NR4A2, EPCAM</td>
<td>Counteract EMT by attenuate cell migration and invasion</td>
<td>(59)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Promote cell apoptosis and cell cycle arrest in response to DNA damage</td>
<td>(59)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Induce apoptosis and cell cycle arrest</td>
<td>(57)</td>
</tr>
<tr>
<td>miR-34a</td>
<td>CD44</td>
<td>Inhibit tumor progenitor cells and suppress metastasis</td>
<td>(60)</td>
</tr>
<tr>
<td></td>
<td>AR</td>
<td>Suppress tumor metastasis</td>
<td>(61)</td>
</tr>
<tr>
<td></td>
<td>CDK6</td>
<td>Induce cell-cycle arrest, cell senescence and apoptosis</td>
<td>(62)</td>
</tr>
<tr>
<td></td>
<td>c-MYC</td>
<td>Inhibit cell proliferation and cell invasion</td>
<td>(32)</td>
</tr>
<tr>
<td></td>
<td>BCL2, SIRT1</td>
<td>Induce cell senescence and apoptosis</td>
<td>(63)</td>
</tr>
<tr>
<td>miR-101</td>
<td>EZH2</td>
<td>Attenuate tumor cell invasiveness</td>
<td>(64,65)</td>
</tr>
<tr>
<td>miR-133</td>
<td>EGFR</td>
<td>Reduce cell proliferation, migration and invasiveness</td>
<td>(66,67)</td>
</tr>
<tr>
<td>miR-146a</td>
<td>ROCK1</td>
<td>Suppress cell metastasis to bone marrow endothelium</td>
<td>(68)</td>
</tr>
<tr>
<td></td>
<td>EGFR, MMP2</td>
<td>Inhibit cell growth, colony formation and migration in vitro</td>
<td>(69)</td>
</tr>
<tr>
<td></td>
<td>EGFR</td>
<td>Reduce tumorigenicity and angiogenesis in vivo</td>
<td>(70)</td>
</tr>
<tr>
<td>miR-15</td>
<td>FGF-2, FGFR1</td>
<td>Impair the tumor-supportive capability of stromal cells</td>
<td>(71)</td>
</tr>
<tr>
<td>miR-16</td>
<td>WNT3A</td>
<td>Attenuate tumor expansion and invasiveness</td>
<td>(72)</td>
</tr>
<tr>
<td></td>
<td>BCL2, CCND1</td>
<td>Induce growth arrest, apoptosis</td>
<td>(72)</td>
</tr>
<tr>
<td>miR-449</td>
<td>HDAC1, CCND1</td>
<td>Induce cell cycle arrest and loss of clonogenicity</td>
<td>(73,74)</td>
</tr>
</tbody>
</table>

miR-143/-145 cluster, which are found down-regulated in metastatic PCa samples (29). Both miR-143 and miR-145 share similar functions in tumor suppression. First, miR-143 is found to exhibit a negative effect on PCa cell proliferation and migration by targeting ERK5 and KRAS, and inactivating subsequent epidermal growth...
factor receptor (EGFR)-RAS-MAPK signaling pathway (46,48). On the other hand, miR-145 is shown to inhibit PCa cell proliferation by targeting Fascin homolog 1 (FSCN1) that is an actin bundling protein involved in cell motility, adhesion and cellular interactions during tumorigenesis and metastasis (50). Second, overexpression of both miRNAs in PC3 cells represses fibronectin and enhances E-cadherin expression and both can reverse EMT and further attenuate the tumor invasiveness in an in vivo bone metastasis model (47). Third, a recent study indicates that both miR-143 and miR-145 can suppress the stem cell characteristics in PC3 cell lines by inhibiting the stem cell markers or factors including CD133, CD44, Oct4, c-Myc and Klf4 (49). Similarly, some studies of embryonic stem cell (ESCs) indicate that miR-145 has been identified to repress pluripotency by targeting Oct4, Sox2, and Klf4 (51,102). Taken together, both miR-143 and miR-145 can suppress several cancer behaviors of PCa cells from tumor proliferation, invasion/metastasis and stemness.

**miR-200 family**

During embryogenesis, EMT is established to determine the transition between epithelial and mesenchymal phenotypes at different developmental stages (103,104). However, during prostatic carcinogenesis, EMT has been highly implicated in PCa progression by initiating the tumor invasiveness (105-107). The consequences of EMT result in the suppression of epithelial markers by transcriptional repressors including ZEB1, ZEB2, SNAI1 and SNAI2, which are found to be the target genes of several tumor suppressive miRNAs including the miR-200 family. The miR-200 family consists of miR-200a, miR-200b, miR-200c, miR-141 and miR-449, which are significantly down-regulated during PCa progression and identified to suppress PCa tumor metastasis particularly via inhibiting EMT. A recent study using PC3 cell line indicates that miR-200 can inhibit the platelet-derived growth factor-D (PDGF-D)-induced acquisition of EMT via targeting of both ZEB1 and ZEB2 (52). Another group studying benign prostate hyperplasia (BPH) also shows that miR-200 can reverse the TGFβ-induced EMT phenotype in BPH cell line (53). Meanwhile, in kidney epithelial cell line, all miR-200 family members have been shown to suppress TGFβ-induced EMT via targeting ZEB1, ZEB2 and SNAI2 in vitro (108,109); Similar result is also found in unilateral urethral obstruction (UUO) model that miR-200 can protect renal tubular epithelial cells from mesenchymal transition via suppressing ZEB1 and ZEB2 in vivo (110). In addition, a regulatory feedback loop has been demonstrated between SNAI2 and the miR-200 family. While miR-200 can target SNAI2 mRNA, SNAI2 protein acts as a repressor to suppress miR-200 gene expression (54). Thus, down-regulation of miR-200 may disrupt the homeostasis between SNAI2 and miR-200. Overall, loss of the miR-200 family in PCa initiates EMT process, which is critical for PCa invasiveness.

**miR-203**

miR-203 is a well-characterized tumor suppressor and shared the similar anti-metastatic function to miR-200.
family (111,112). MiR-203 has been demonstrated to induce MET in PC3 and DU145 cell lines via targeting CKAP2, LASP1, BIRC5, WASF1, ASAP1, and RUNX2, which are critical effectors involved in cell proliferation, migration, invasion and EMT (55). Meanwhile, other study also suggests that miR-203 exhibits its negative effect on multiple steps of the PCa metastatic cascade via targeting on pro-metastatic molecules including ZEB2, Bmi, survivin, and Runx2. As a result, restoration of miR-203 in PC3, VCaP, and MDA-PCa-2b cell lines attenuates the invasiveness of PCa bone metastasis in vivo (56). This evidence suggests miR-203 play an important role in the metastatic progression of PCa and that loss of miR-203 may further enhance the invasive characteristics of advanced PCa.

miR-205
Similar to miR-203, miR-205 regulates PCa progression by targeting EMT signaling mechanisms (113). Restoration of miR-205 in PCa cells can induce MET phenotype by up-regulation of E-cadherin, along with attenuated cell invasiveness. In a more detailed study, miR-205 is suggested to attenuate cell invasion and migration via targeting ErbB3, E2F1, E2F5 and protein kinase Cε (PKCε) (58). Meanwhile, another study using xenograft model with tail vein injection also demonstrates that miR-205 can inhibit PCa lung metastasis in vivo by targeting ZEB1 and vimentin (114). In addition to EMT regulation, miR-205 can also promote PCa cell apoptosis and cell-cycle arrest by targeting the anti-apoptotic gene BCL2 (59). Moreover, miR-205 is able to inhibit tumor cell growth by inducing apoptosis and cell cycle arrest via targeting AR co-regulators (DJ-1, PSAP, ARA24) and MAPK signaling components (57). These accumulating findings indicate that both miR-203 and miR-205 may suppress metastatic progression of PCa by impairing the EMT-induced invasiveness.

miR-34a
In PCa, miR-34a is identified as a tumor suppressor by inhibiting the stemness characteristics of prostate cancer stem cells (CSC) (61). The study demonstrates that miR-34a is down-regulated in the CD44 + PCa cells purified from xenograft tumors; overexpression of miR-34a can attenuate clonogenic expansion, tumor regeneration, and metastasis in CD44 + PCa cells. These results suggest that miR-34a is a negative regulator of prostate CSC and may exert its suppressive effect on PCa progression before the onset of metastatic CRPC. Moreover, miR-34a appears to be a p53-regulated gene from a study (115) using doxorubicin and camptothecin-induced p53 activation that a significant up-regulation of both miR-34a and miR-34c is shown. However, this p53-mediated miR-34a up-regulation is abolished in both AR-knockdown LNCaP cells and AR-negative cell lines including PC3 and DU145, suggesting miR-34a expression is AR-dependent. On the other hand, AR has been identified as a direct target gene of miR-34a (62); AR activity can be repressed by de-methylation of epigenetically silenced miR-34a promoter in PCa cells. Overall, these findings imply a reciprocal transcriptional regulatory network among miR-34a, p53 and AR in PCa cells. However, whether this network is involved in PCa progression and its clinical significance require further investigation. Another target gene of miR-34a is c-Myc (63). By targeting the c-Myc expression, miR-34a is shown to suppress the signaling cascade of c-Myc-Skp2-Miz1, which leads to RhoA gene expression and subsequent attenuates cell migration and invasion. In addition to PCa stemness and metastasis, miR-34a also affect the PCa tumor growth by inducing cell-cycle arrest, cell senescence and apoptosis via targeting cell-cycle regulatory gene, such as CDK6 (32), and anti-apoptosis genes including Bcl-2 and SIRT1 (64,65). Overall, miR-34a may exert its tumor suppressor role via targeting various signaling molecules at different stages of PCa progression.

miR-101
Ezh2 is a histone methyltransferase that regulates epigenetic silencing and early studies have demonstrated that overexpression of Ezh2 in PCa contributes to the enhanced aggressiveness and metastatic potential of PCa cells (116-119). A study shows an inverse correlation between miR-101 and Ezh2 expression has been observed in human PCa. Meanwhile, miR-101 is found to suppress the expression and function of Ezh2 in PCa cell lines (66) and the overexpression of miR-101 in PC3, DU145 and LNCaP cells also results in the suppression of Ezh2, along with attenuated cell invasion and migration of these PCa cell lines in vitro (67,117). These findings clearly indicate the role of miR-101 in the epigenetic regulation critical for PCa progression via targeting Ezh2 expression.

miR-133 and miR-146a
Epidermal growth factor (EGF) and EGFR are known...
to be key tumor promoter for PCa (120). A recent study indicates that, under hypoxia condition, EGFR can interrupt the biogenesis of mHESM (miRNAs regulated by hypoxia-dependent EGFR-suppressed maturation) resulted in reducing Dicer binding and abolishing miRNA maturation via targeting AGO2 phosphorylation (121). Implying that EGFR may certainly contribute to the modification of miRNA processing. On the other hand, both miR-133 and miR-146a have been shown to suppress PCa tumor progression via targeting EGFR. Down-regulation of miR-133 has been observed in PC3 and DU-145 cell lines. Ectopic expression of miR-133 can reduce cell proliferation, migration and invasiveness by targeting EGFR (68). Similar to miR-133, expression level of miR-146a is also significantly down-regulated in PCa (122,123). Overexpression of miR-146a has been demonstrated to suppress PCa cell growth, colony formation and migration in vivo via targeting EGFR. Additional studies also reveal that miR-146a can inhibit angiogenesis and bone metastasis in vivo by suppressing both matrix metalloproteinase-2 (MMP2) and Rho-associated, coiled-coil containing protein kinase 1 (ROCK1) expression (69,70). These findings indicate that loss of both miR-133 and miR-146a in PCa may attribute to enhancement of EGFR signaling, leading to aggressive PCa progression.

miR-15a and miR-16-1

miR-15a and miR-16-1 are in the same cluster; the expression of miR-15a/miR-16-1 is often down-regulated in PCa due to chromosomal deletion at 13q14, which is highly correlated with the progression of PCa (124). A study has demonstrated that miR-15a/miR-16-1 level is inversely correlated with B-cell lymphoma 2 (BCL2), cyclin-D1 (CCND1) and wingless-type 3A (WNT3A) in advanced PCa (72). The same group also found that both CCND1 and WNT3A are putative target genes of miR-15a/miR-16-1. As a result, restoration of miR-15a and miR-16 is shown to arrest cell growth and induce apoptosis and knockdown of mir-15a/miR-16-1 can promote survival, proliferation and invasiveness of PCa xenograft tumor in vivo. On the other hand, miR-15a and miR-16-1 also exert tumor suppressive effects by interfering the stromal support in the tumor microenvironment since interaction between tumor cells and the surrounding cellular components is critical for tumor development (125,126). It has been indicated that down-regulation of miR-15a and miR-16 in cancer-associated fibroblasts results in tumor expansion and invasion (72), which is supported by the reconstitution of both miRNAs in fibroblast can interrupt the stromal support by targeting FGF-2 and FGFR1 (71). All these data indicate that the tumor suppressor role of miR-15a/ miR-16-1 is to suppress cancer cells or interrupt their communication with the microenvironment.

miR-449a

miR-449a is inversely correlated with the expression of histone deacetylase 1 (HDAC1)-an enzyme critical for epigenetic regulation. It has been indicated that increased expression of miR-449a in PCa cell lines leads to both cell cycle arrest and loss of clonogenicity by targeting HDAC1 (73). In addition, miR-449 can initiate cell cycle arrest and induce cell senescence by targeting cyclinD1 (74).

Oncogenic miRNAs

miR-21

The recurrence of CRPC is often associated with hyperactivation of AR. Recent studies have suggested that several oncogenic miRNAs is correlated with aberrant AR activation. In particular, miR-21 is an AR-regulated miRNA and its expression level is consistently elevated from androgen-dependent PCa to CRPC (127). Overexpression of miR-21 can support xenograft tumor growth and induce castration-resistant phenotype (75). In addition to androgen response element (ARE), other cis-elements such as AP-1 and STAT-3 are also found in the promoter region of miR-21 (24,25). AP-1 activity is closely associated with CRPC recurrence (128) and STAT-3 is also shown to be involved in PCa metastasis (129). Overall, the highly elevation of miR-21 may be attributed to the aberrant expression of transcriptional activators such as AR and AP-1. The subsequent effect of miR-21 overexpression in turn contributes to the development of prostate tumorigenesis. Several target genes of miR-21 have been shown to suppress tumor progression by inhibiting invasiveness, promoting apoptosis and cell cycle arrest. For example, myristoylated alanine-rich protein kinase c substrate (MARCKS) is a direct target of miR-21, which plays key role in cell motility, membrane trafficking and mitogenesis. Thus, miR-21 promotes the apoptosis resistance, cell motility and invasiveness of PC3 and DU-145 cells partly via targeting MARCKS (77). Meanwhile, a recent study demonstrates that reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is another novel target of miR-21; An
inverse correlation between RECK and miR-21 has been shown from different stages of PCa (76).

**miR-125b**

Similar to miR-21, miR-125b is also an AR-induced miRNA. The induction of miR-125b in LNCaP cells inhibits apoptosis and enhances cell proliferation. Mechanistically, miR-125b promotes PCa xenograft tumor growth by targeting major pro-apoptotic genes including p53, Puma and BAK1 (78). Consistent with this observation, miR-125b is shown to modulate the p53 network by interrupting Mdm2 degradation via targeting p14ARF, which mediates the Mdm2 sequestration (80). Overall, miR-125b can target the p53-p21 and Puma signaling network, leading to enhanced cell proliferation in both LNCaP and CWR22Rv1 PCa cell lines through p53-dependent and p53-independent manner, respectively.

**miR-221 and miR-222**

Both miR-221 and miR-222 belong to the same miRNA cluster. Overexpression of miR-221/miR-222 has been often found in PCa. The aberrant elevation of miR-221/miR-222 is highly correlated with metastatic CRPC phenotypes. Moreover, an inverse correlation between miR-221/miR-222 expression and p27Kip1 level has been observed in primary PCa. Several studies demonstrated that miR-221/miR-222 can up-regulate S-phase kinase associated protein 2 (Skp2), cyclin A and cyclin D1 via targeting p27Kip1 suppression, leading to cell cycle progression at G1-to-S phase, increased clonogenicity in vitro and enhanced tumorigenicity in vivo (83,84,130). Meanwhile, Ras homolog member I (ARHI), a tumor suppressor identified in ovarian cancer (131), is also identified as the target gene of miR-221/miR-222. Overexpression of ARHI in PC3 cells results in the inhibition of cell proliferation, colony formation, cell invasion and survival (81,82,132), suggesting decreased ARHI mRNA could be an additional mechanism for miR-221/miR-222 contributing to the accelerated tumor growth in PCa. Thus, these data conclude the functional role of miR-221/miR-222 as PCa promoter by targeting tumor suppressor genes such as p27Kip1 and ARHI.

**miR-32**

miR-32 is highly expressed in CRPC specimens compared to BPH specimens (85). A study demonstrated that miR-32 exerts oncogenic characteristics by targeting on both B-cell translocation gene 2 (BTG-2) and phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), which regulates the inhibition of PI3K, a well-known regulator of cell proliferation, migration and survival (85). An inverse correlation between miR-32 and BTG-2 has been found in the CRPC specimens (85). In addition, numerous studies have identified BTG-2 as a critical target gene of AR-regulated miRNAs including miR-32, miR-148 and miR-21 (85,86). Loss of BTG-2 was implicated in the progression of PCa accompanied by the appearance of EMT markers (133). Meanwhile, a study using LNCaP cells demonstrated that miR-32 facilitates cell growth by inhibiting cell apoptosis and enhancing cell proliferation, respectively. Overall, miR-32 exerts its oncogenic characteristics by targeting on tumor suppressors critical for cell proliferation, survival and migration.

**miR-148a**

Similar to miR-32, miR-148 is elevated in advanced PCa compared to primary tumor (134). However, in contrast to the distinctive oncogenic role of miR-32, the role of miR-148a in PCa progression is more controversial. For example, miR-148a was identified as an androgen-responsive miRNA and facilitates LNCaP cell proliferation via targeting cullin-associated and neddylation-dissociated 1 (CAND1) (87). In contrast, miR-148a is shown to be down-regulated in both DU-145 and PC3 cell lines. Furthermore, overexpression of miR-148a in PC3 cells attenuates cell growth, migration, invasion, and enhances the drug sensitivity to Paclitaxel. This phenomenon is paralleled with the effect in MSK1-knockdown PC3 cells. In particular, MSK1 has been identified as the target gene of miR-148a, suggesting miR-148a attenuates the drug-resistance of CRPC cells via targeting MSK1 (135). Apparently, miR-148a represents a unique miRNA with dual function in PCa. Although the exact mechanism remains undetermined, AR may be an important factor involved in miR-148a function or the presence of different target genes of miRNA-184a in PCa cells derived from different origins.

**miR-106b/miR-25**

A study (136) using computational approach to identify PTEN-target miRNAs has identified miR-106b/miR-25 as a candidate that is concomitantly overexpressed with
its host gene, minichromosome maintenance protein 7 (MCM7), which result in enhanced cell transformation and initiated prostatic intraepithelial neoplasia (PIN) progression of PCa. This study has a significant finding to show a cooperative expression of an oncomir cluster with its oncogenic host gene, which could simultaneously generate “two-hits” effect on the malignant transformation of normal cells. In addition, a study using LNCaP cell line has demonstrated that miR-106b/miR-25 cluster is associated with PCa progression by targeting caspase 7, apoptosis-related cysteine peptidase (CASP7) mRNA, which is downregulated in both primary PCa and metastatic lesions (134). Overall, miR-106b/miR-25 cluster is an oncomir cluster and it is often found altered in its expression level between PIN, primary, and metastatic PCa (86,137).

Conclusions

miRNA represents a new mechanism of regulating gene expression at either post-transcriptional or translational levels. Aberrant alteration of miRNAs has been clearly demonstrated in PCa. However, knowing complex regulatory mechanism and relationship of miRNAs and their multiple target genes have further complicated their functionality during carcinogenesis. Therefore, carefully dissecting the mechanisms and functional role of each miRNA in heterogeneous PCa cells will certainly generate new information that could be applied as biomarker(s) and developed into novel therapeutic strategies.

Acknowledgements

This work was supported in part by grants from the United States Army (W81XWH-11-1-0491 to JTH).

Disclosure: The authors declare no conflict of interest.

References


41. Xu B, Niu X, Zhang X, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.


73. Noonan EJ, Place RF, Pookot D, et al. miR-449a targets...


124. Qu Y, Li WC, Hellem MR, et al. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-

Cite this article as: Lo UG, Yang D, Hsieh JT. The role of microRNAs in prostate cancer progression. Transl Androl Urol 2013;2(3):228-241. doi: 10.3978/j.issn.2223-4683.2013.08.01
Abstract:

Background: MicroRNAs (miRNA) are small noncoding RNA molecules regulating multiple biological processes via post-transcriptional suppression, mRNA degradation or translational inhibition. Functionally, miRNAs can either promote or inhibit cancer development. For example, each member of miR17-92 cluster is characterized as oncogenic miRNA. In contrast, miR-363 belongs to the polycistronic miR106a-363 cluster that is closely resembled to the oncogenic miR17-92 cluster. However, no miR-363 homolog is present in the miR-17-92 cluster and its regulation and functional role in cancer are not well understood.

Results: The acquisition of epithelial-to-mesenchymal transition (EMT) is a hallmark of cancer cells to increase their invasive potentials leading to the initiation of metastases. We unveil the function of miRNA-363 (miR-363) as a potent anti-EMT miRNA in prostate cancer (PCa), renal cancer and liver cancer, which is distinct from the rest of miRNAs in miR106a-363 cluster. Noticeably, our work provides a new mechanistic insight of miR-363 regulation within the miR-106a-363 cluster by interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) first characterized as a viral RNA binding protein. IFIT5 appears to recognize the unique 5'-end sequence of miR-363 and coordinates with XRN1 to specifically degrade miR-363 but not other miRNAs in this cluster. We further demonstrate that IFIT5 can elicit EMT via miR-363 turnover in PCa. Clinically, IFIT5 is highly elevated in high-grade PCa with an inverse correlation of miR-363

Conclusion: Our finding unveils miR-363 as anti-EMT miRNA and identifies IFIT5 complex as a new machinery of miRNA turnover that is specific for the degradation of a tumor suppressive miRNA derived from a cluster containing mostly oncogenic miRNAs.
Jiancheng Zhou  
Shu-Fen Tseng  
Jer-Tsong Hsieh

**Order of Authors Secondary Information:**

**Suggested Reviewers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jindan Yu</td>
<td><a href="mailto:jindan-yu@northwestern.edu">jindan-yu@northwestern.edu</a></td>
</tr>
<tr>
<td>Rajvir Dahiya</td>
<td><a href="mailto:RDahiya@ucsf.edu">RDahiya@ucsf.edu</a></td>
</tr>
<tr>
<td>Leland Chung</td>
<td><a href="mailto:leland.chung@cshs.org">leland.chung@cshs.org</a></td>
</tr>
<tr>
<td>Martin Gleave</td>
<td><a href="mailto:m.gleave@ubc.ca">m.gleave@ubc.ca</a></td>
</tr>
<tr>
<td>Robert Matusik</td>
<td><a href="mailto:robert.matusik@mcmail.vanderbilt.edu">robert.matusik@mcmail.vanderbilt.edu</a></td>
</tr>
<tr>
<td>George Thalmann</td>
<td><a href="mailto:George.Thalmann@insel.ch">George.Thalmann@insel.ch</a></td>
</tr>
<tr>
<td>Kathleen Collins</td>
<td><a href="mailto:kcollins@berkeley.edu">kcollins@berkeley.edu</a></td>
</tr>
<tr>
<td>Natasha Kyprianou</td>
<td><a href="mailto:nkypr2@uky.edu">nkypr2@uky.edu</a></td>
</tr>
</tbody>
</table>

**Additional Information:**

<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Has this manuscript been submitted to this journal before?</td>
<td>No</td>
</tr>
<tr>
<td><strong>Experimental design and statistics</strong></td>
<td>Yes</td>
</tr>
<tr>
<td>Full details of the experimental design and statistical methods used should be given in the Methods section, as detailed in our Minimum Standards Reporting Checklist. Information essential to interpreting the data presented should be made available in the figure legends.</td>
<td></td>
</tr>
<tr>
<td>Have you included all the information requested in your manuscript?</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Resources**

A description of all resources used, including antibodies, cell lines, animals and software tools, with enough information to allow them to be uniquely identified, should be included in the Methods section. Authors are strongly encouraged to cite Research Resource Identifiers (RRIDs) for antibodies, model organisms and tools, where possible.

<table>
<thead>
<tr>
<th>Resources</th>
<th>Yes</th>
</tr>
</thead>
</table>

 Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
<table>
<thead>
<tr>
<th>Availability of data and materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>All datasets and code on which the conclusions of the paper rely must be either included in your submission or deposited in publicly available repositories (where available and ethically appropriate), referencing such data using a unique identifier in the references and in the “Availability of Data and Materials” section of your manuscript.</td>
</tr>
<tr>
<td>Have you have met the above requirement as detailed in our Minimum Standards Reporting Checklist?</td>
</tr>
</tbody>
</table>
A new microRNA turnover machinery mediated by IFIT5 complex leading to epithelial-to-mesenchymal transition

U-Ging Lo¹, Rey-Chen Pong¹, Diane Yang¹, Leah Gandee¹, Jiancheng Zhou², Shu-Fen Tseng³, and Jer-Tsong Hsieh¹,⁴

¹Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; ²Department of Urology, The First Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710049, China; ³Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; ⁴Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung 40447, Taiwan, Republic of China

Corresponding author:

Jer-Tsong Hsieh, Ph.D., jt.hsieh@utsouthwestern.edu, Phone: 214-648-3988; Fax: 214-648-8786; 5323 Harry Hines Blvd., J8-134 Dallas, TX 75390, USA.
ABSTRACT

**Background:** MicroRNAs (miRNA) are small noncoding RNA molecules regulating multiple biological processes via post-transcriptional suppression, mRNA degradation or translational inhibition. Functionally, miRNAs can either promote or inhibit cancer development. For example, each member of miR17-92 cluster is characterized as oncogenic miRNA. In contrast, miR-363 belongs to the polycistronic miR106a-363 cluster that is closely resembled to the oncogenic miR17-92 cluster. However, no miR-363 homolog is present in the miR-17-92 cluster and its regulation and functional role in cancer are not well understood.

**Results:** The acquisition of epithelial-to-mesenchymal transition (EMT) is a hallmark of cancer cells to increase their invasive potentials leading to the initiation of metastases. We unveil the function of miRNA-363 (miR-363) as a potent anti-EMT miRNA in prostate cancer (PCa), renal cancer and liver cancer, which is distinct from the rest of miRNAs in miR106a-363 cluster. Noticeably, our work provides a new mechanistic insight of miR-363 regulation within the miR-106a-363 cluster by interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) first characterized as a viral RNA binding protein. IFIT5 appears to recognize the unique 5’-end sequence of miR-363 and coordinates with XRN1 to specifically degrade miR-363 but not other miRNAs in this cluster. We further demonstrate that IFIT5 can elicit EMT via miR-363 turnover in PCa. Clinically, IFIT5 is highly elevated in high-grade PCa with an inverse correlation of miR-363.

**Conclusion:** Our finding unveils miR-363 as anti-EMT miRNA and identifies IFIT5 complex as a new machinery of miRNA turnover that is specific for the degradation of a tumor suppressive miRNA derived from a cluster containing mostly oncogenic miRNAs.

**Key Words:** IFIT5, XRN1, microRNA-363, EMT
BACKGROUND

MicroRNAs (miRNA) are a large family of short sequence single-stranded noncoding RNAs, which has been shown to regulate approximate 60% protein-coding genes via post-transcriptional suppression by facilitating mRNA degradation, or translational inhibition[1, 2]. Until now, many miRNAs have been identified to be associated with different stages of tumor development. Based on the seed sequence of 2-7 nucleotides, miRNAs are grouped into different families for predicting the potential target gene(s); the function of miRNAs could be divided into onco-miRNAs and tumor suppressor miRNAs. However, only handfulls of them have been validated experimentally. In this study, we clearly identify a unique miR-363 that is able to inhibit EMT in PCa by targeting Slug/SNAI2 mRNA. Clinically, a reduced miR-363 expression is correlated with PCa malignancy.

In general, similar to most protein-coding genes, miRNA genes can be regulated at transcriptional or post-transcriptional level [3]. Unlike most eukaryotic protein genes, several miRNAs such as miR-106a-363 [4] and miR-17-92 are clustered together to generate a polycistronic primary transcript [5-7], which further complicates the regulatory scheme of miRNA biogenesis because each individual miRNA derived from one cluster may have different functional roles as well as expression levels in any given cell or tissue. For example, miR-363 belongs to the polycistronic miR-106a-363 cluster containing six miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363), located on chromosome X. Unlike the other five miRNAs with similar seed sequences and similar functions as the oncogenic miR-17-92 cluster [8], miR-363 has been implicated to play a tumor suppressor role in nasal-type natural killer/T-cell lymphoma [9], hepatocellular carcinoma [10] and colorectal cancer [11]. In this study, we unveil a new post-transcriptional regulatory mechanism specific to miR-363 turnover by a novel protein complex- Interferon-induced protein with tetratricopeptide repeats 5 (IFIT5), and our results further support the tumor suppressive role of miR-363 in several cancer cells.

IFIT protein family was first identified as a viral RNA binding protein [12] as a part of antiviral defense mechanisms by intervening viral replication and/or disrupting viral RNA translation in host cells. Among IFIT orthologs, human IFIT1, IFIT2 and IFIT3 form a complex through the tetratricopeptide repeats (TPR) to degrade viral RNA. On the contrary, IFIT5 acts solely as a monomer and binds directly to RNA molecules via its convoluted RNA-binding cleft. In a recent
study, IFIT5 has been shown to directly bind to endogenous cellular RNA with a 5’-end phosphate cap, including transfer RNA (tRNA) [13, 14], which partially shared a structural similarity with the precursor form of small RNAs such as small hairpin RNA (shRNA) and primary or precursor miRNAs. This is the first time in the literature to demonstrate that IFIT5 is able to specifically recognize a unique structure in the precursor miR-363 (pre-miR-363) and can facilitate the recruitment of XRN1 to degrade pre-miR-363. Also, the expression level of IFIT5 is inversely correlated with that of miR-363 in PCa specimens. In addition, a significant elevation of IFIT5 is detected in several cancer cells expressing EMT phenotypes associated with invasiveness. Thus, IFIT5-XRN1 complex mediates a specific degradation of tumor suppressor miRNA from its cluster, which could provide a new understanding of miRNA biogenesis for other tumor suppressor miRNAs.
RESULTS AND DISCUSSION

The specific correlation between DAB2IP and miR-363 expression. DAB2IP is known as a potent regulator in EMT leading to cancer metastases [15, 16]. However, the detailed mechanism of action of DAB2IP is not fully characterized. As emerging evidence demonstrates the critical role of miRNA in the EMT process of PCa, we therefore performed miRNA microarray screening (Additional file 1A and 1B) that resulted in the identification of a unique miRNA-miR-363 that is significantly decreased in DAB2IP-knockdown (KD) cells. The down-regulation of miR-363 in DAB2IP-KD cells was further validated in not only prostate cell lines (LAPC-4, RWPE1, PC3 and PNT1A) (Fig. 1A) but also renal cell lines such as 786-O-KD and HK2-KD (Fig. S1C). Ectopic expression of DAB2IP in C4-2Neo or LAPC4-KD cells (Fig. 1B), or HEK293 (Fig. S1D) was able to induce mature miR-363 levels in a dose-dependent manner, indicating that DAB2IP could modulate miR-363 expression.

MiR-363 is located in the polycistronic miR-106a-363 cluster that is first transcribed into a single primary miRNA containing the entire sequence of the cluster genes. We therefore examined the effect of DAB2IP on the expression levels of primary transcript of miR-106a-363. In contrast to the significant down-regulation of mature miR-363 in DAB2IP-KD cells, the expression levels of primary miR-106a-363 were similar between DAB2IP-positive and -negative cells (Fig. 1C). Also, the expression levels of precursor miR-363 (pre-miR-363) showed no significant difference between these cells (Fig. 1D). Noticeably, only the mature miR-363 levels dramatically decreased in DAB2IP-KD cells (i.e., LAPC4-KD and RWPE1-KD) (Fig. 1E). On the other hand, only the mature miR-363 levels increased significantly in DAB2IP-expressing cells (i.e., C4-2D2) (Fig. 1E). Similar result was also observed in HEK293 cells (Additional file 1E). These findings indicate that DAB2IP specifically regulates miR-363 maturation process from the miR-106a-363 cluster.

The impact of IFIT5 on miR-363 biogenesis distinct from miR-106a-363 cluster. In order to elucidate the machinery responsible for miR-363 maturation process, the protein candidates were pulled down by precursor miR-363 and analyzed by LC-MS/MS (Additional file 9, Table 1) to unveil IFIT5 protein as a potential hit. Indeed, the steady-state levels of IFIT5 mRNA and protein were inversely correlated with DAB2IP (Additional file 2A). IFIT5 is characterized as viral RNA or cellular tRNA binding protein and has not been known for its binding ability to
microRNA. Therefore, the specific association between pre-miR-363 and IFIT5 was further validated using RNA pull-down (Fig. 2A). This inhibitory effect of DAB2IP on IFIT5 expression was further confirmed by the ectopic expression of DAB2IP in LAPC4-KD (Fig. 2B), C4-2Neo (Fig. 2C), LNCaP (Additional file 2B), and HEK293 cells (Additional file 2C).

To further examine whether IFIT5 plays a critical role in DAB2IP-mediated miR-363 maturation, ectopic expression of IFIT5 in DAB2IP-positive cells resulted in a significant reduction of mature miR-363 levels but not the other mature miRNAs from the same cluster (Fig. 2D, 2E, and 2F). In addition, applying 3 different IFIT5 small interfering RNA (siRNA) onto LAPC4-KD cells, the levels of mature miR-363 were correlated with the knockdown efficiency of each siRNA on endogenous IFIT5 mRNA levels (Additional file 2D). Thus, the IFIT5-C siRNA was chosen; and the reduced IFIT5 resulted in a significant elevation of mature miR-363 in a dose-dependent manner (Additional file 2E). Despite of the significantly elevated mature miR-363 in IFIT5-KD cells, the levels of mature miR-106a, miR-18b, miR-20b, miR-19b-2 and miR-92a-2 remained relatively unchanged (Fig. 2G, 2H, 2I and Additional file 2F). Meanwhile, the expression levels of pre-miR-363 and other pre-miRNAs from the same cluster remained unchanged in these IFIT5-KD cells (Additional file 2G). Taken together, IFIT5 can specifically inhibit the miR-363 maturation from miR-106a-363 cluster.

The effect of IFIT5 on miR-363 turnover at precursor stage. In a recent study, IFIT5 has been suggested to suppress virus replication by targeting 5’-phosphate single stranded viral RNA for rapid turnover [14]. Thus, we examined whether IFIT5 has a direct impact on the stability of pre-miR-363. In fact, pre-miR-363 RNA prepared from in vitro transcription was relatively stable at 37°C (Additional file 3A). However, the presence of IFIT5 protein immunoprecipitated (IP) from LAPC4-Con cells significantly increased the turnover rate of pre-miR-363 RNA (Additional file 3A), indicating that the degradation of pre-miR-363 is accelerated by IFIT5 complex. To examine the specificity of IFIT5 in the acceleration of pre-miR-363 turnover, we determined the turnover rate of pre-miR-92a-2 (immediate adjacent to miR-363) in the presence of IFIT5 and found no significant change (Fig. 3A). Previous studies [12, 13] indicate that IFIT5 protein binds to viral RNA molecules at either 5’-phosphate cap or 5’-tri-phosphate group. By comparing the 5’-end structure between pre-miR-92a-2 and pre-miR-363, we hypothesized that a single nucleotide (uracil) overhang in pre-miR-363, in contrast to the double-stranded blunt end
in pre-miR-92a-2 is critical for IFIT5 recognition. Therefore, we generated 2 mutant pre-miR-363 constructs: one with 5’-end six nucleotides single stranded overhang (SS\textsuperscript{6}Mut pre-miR-363) and the other with double-stranded blunt end (DSMut pre-miR-363) (Fig. 3B) to test their stabilities. The result (Fig. 3B) indicated that the expression levels of primary miR-363 from either native or mutants were similar. However, the expression levels of pre-miR363 or mature miR-363 derived from SS\textsuperscript{6}Mut were significantly lower than those from native or DSMut form (Fig. 3B), indicating that the 5’-end structure of pre-miR-363 dictates the stability of miR-363 maturation. Similar pattern of mature miR-363 expression was also detected in RWPE1-KD cells (Additional file 3B). By determining the \textit{in vitro} degradation rates of pre-miR-363, SS\textsuperscript{6}Mut and DSMut pre-miR-363 RNA molecules, as we expected, SS\textsuperscript{6}Mut pre-miR-363 was very sensitive to IFIT5 whereas DSMut pre-miR-363 was the most resistant one (Fig. 3C). Furthermore, we observed a steady elevation of SS\textsuperscript{6}Mut -derived mature miR-363 level in a dose-dependent manner in the presence of an incremental IFIT5 siRNA, while the expression of DSMut-derived mature miR-363 remained at high levels and was not affected by IFIT5 siRNA (Fig. 3D). Meanwhile, using RNA pull-down assay, SS\textsuperscript{6}Mut pre-miR-363 exhibited higher affinity to IFIT5 than DSMut pre-miR-363 (Fig. 3E). In contrast, DICER, one of the key endoribonuclease for miRNA maturation, exhibited higher interaction with DSMut pre-miR-363 than SS\textsuperscript{6}Mut pre-miR-363. These data conclude that IFIT5 recognizes the unique 5’-end overhanging structure in pre-miR-363 to elicit its degradation activities.

To further this specific recognition between the unique 5’-end structure of pre-miRNA and IFIT5 complex, we also generated a mutant construct of pre-miR-92a-2 with single nucleotide at 5’overhang (SS\textsuperscript{1}Mut pre-miR-92a-2) (Fig. 3F), which shared a structural similarity to the 5’-end of pre-miR-363 (Fig. 3B). Using RNA pull-down assay, we observed significantly higher interaction between SS\textsuperscript{1}Mut pre-miR-92a-2 and IFIT5 protein than pre-miR-92a-2 (Fig. 3F). Moreover, the degradation rate of SS\textsuperscript{1}Mut pre-miR-92a-2 increased in the presence of IFIT5 complex, compared to that of pre-miR-92a-2 (Additional file 3C). In addition, we generated a mutant pre-miR-18b with double nucleotide overhang at its 5’end (SS\textsuperscript{2}Mut pre-miR-18b). Similarly, the significantly higher interaction between SS\textsuperscript{2}Mut pre-miR-18b and IFIT5 protein was observed (Fig. 3G) and the degradation rate of SS\textsuperscript{2}Mut pre-miR-18b RNA molecule was significantly elevated as well (Additional file 3D). Overall data indicate that IFIT5-mediated precursor miRNAs turnover is determined by the 5’-end overhanging structure.
The role of XRN1 in IFIT5-mediated miR-363 turnover. Although IFIT5 can elicit miR-363 turnover, IFIT5 doesn’t possess ribonuclease activity. We further examined LC-MS/MS results and identified an exoribonuclease candidate-XRN1. XRN1 is known to regulate mRNA stability via cleavage of de-capped 5’-monophosphorylated mRNA [17, 18] and a recent study also implied its potential role in miRNA turnover [19]. Indeed, an interaction was observed between IFIT5 and XRN1 protein in LAPC4-Con cells (Fig. 4A). Also, XRN1 exhibited a similar expression pattern as that of IFIT5 between DAB2IP-negative and DAB2IP-positive cells (Additional file 4A) and the presence of DAB2IP was able to inhibit XRN1 expression (Fig. 4B and Additional file 4B). Using 3 different XRN1 siRNAs in LAPC4-KD cells, the elevated expression levels of miR-363 were correlated with the diminished level of XRN1 protein (Fig. 4C and Additional file 4C). Similar to IFIT5-KD, data from XRN1-KD cells clearly demonstrated only mature miR-363 exhibited a significant accumulation whereas other mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, and miR-92a-2) remained relatively unchanged (Fig. 4D).

Also, by incubating XRN1 proteins from IP (Additional file 4D) with native, SS6Mut or DSMut pre-miR-363 RNA molecules, a significant increase of both native and SS6Mut pre-miR-363 degradation was detected in a time-dependent manner, whereas DSMut pre-miR-363 remained unchanged (Fig. 4E and Additional file 4D), implying that IFIT5 binding structure in the 5’-end of pre-miR-363 is critical for recruiting XRN1. Indeed, by ectopic transfection IFIT5 cDNA into XRN1-expressing LAPC4-Con cells, the presences of IFIT5 significantly facilitated the turnover rate of SS6Mut -pre-miR-363 (Fig. 4F and Additional file 4E). On the other hand, by knocking down XRN1 in IFIT5-expressing LAPC4-Con cells, loss of XRN1 diminished the degradation rate of SS6Mut pre-miR-363 (Fig. 4G and Additional file 4F) and rescued the mature miR-363 levels (Fig. 4H). These findings provide further evidence for the specific function of IFIT5-XRN1 complex in miR-363 turnover.

XRN family has been identified as a 5’- to 3’-exoribonuclease responsible for the fidelity of mRNA turnover in eukaryotes [20, 21]. In particular, XRN1 mainly targets the degradation of de-capped mRNA or long non-coding RNAs (lncRNAs), whereas XRN2 is required to degrade a nascent pre-mRNA to prevent long aberrant mRNA formation [18]. Several studies indicated the correlation between XRN family and miRNA biogenesis. For example, XRN2 has been
identified to regulate mature miRNA turnover during *C. elegans* development [22], while XRN1 is shown to regulate miR-277-3p expression in Drosophila [19] and mediates a selective decay of miR-382 in human HEK293 cells [23]. Nevertheless, our data further unveil the specific action of XRN1 as the key ribonuclease in miRNA degradation.

**The C-terminal TPR domain of IFIT5 is required for docking XRN1 on pre-miR-363.** Structurally, the C-terminal TPR helices, especially the TPR7 and 8, of IFIT5 are key binding domains for 5'-phosphate capped RNA [12, 13]. Indeed, our data (Fig. 5A and Additional file 5A) clearly demonstrated that ΔTPR7-8 (Δ7-8) mutant of IFIT5 lost its ability to degrade miR-363 compared to wild type (WT) IFIT5 because both domains appeared to be critical for the binding to pre-miR-363 RNA and the interacting with XRN1 protein (Fig. 5B and Additional file 5B), which was further confirmed by IP (Fig. 5C). Previously single amino acid mutation (K415A and K422A) in the helix domain between TPR7 and 8 domain of IFIT5 can abolish its binding ability [13], however, our data indicated that both still retained the most of inhibitory activities (Fig. 5A and Additional file 5A) as well as their interaction with XRN1 protein (Fig. 5B and Additional file 5B)

We further determined whether SS6Mut or DSMut pre-miR-363 could influence the *in vitro* interaction of IFIT5 and XRN1 in which IFIT5-XRN1 complex was determined by IP with IFIT5 in the presence of incremental amounts of SS6Mut or DSMut pre-miR363. Clearly, only SS6Mut but neither DSMut nor pre-miR-92a-2 could facilitate the complex formation between IFIT5 and XRN1 (Fig. 5D and Additional file 5C). Taken together, the C-terminal TPR7-8 domain of IFIT5 protein is critical for not only recognizing the 5'-end overhang structure in pre-miR-363 RNA but also facilitating the docking of XRN1 on pre-miR-363.

**The functional role of miR-363 in EMT.** DAB2IP is known to inhibit EMT process via regulating several of the embryonic development genes [16] that can be potential target gene(s) of miR-363 based on predicted sequences. From profiling genes modulated by miR-363 in LAPC4-KD cells and RWPE1-KD cells, Slug/SNAI2 mRNA appears to be a potential candidate target gene. Indeed, the suppression of Slug/SNAI2 mRNA and protein levels was detected in miR-363 expressing cells as compared to their controls (Fig. 6A and Additional file 6A). Moreover, the six nucleotides sequence in 3'-end un-translational region (3'-UTR) of
Slug/SNAI2 mRNA matches the seed region of mature miR-363 (Additional file 6B). By constructing both wild type Slug/SNAI2 3’UTR (Slug-WT3’UTR) and mutant Slug/SNAI2 3’UTR (Slug-Mut$^{363}$3’UTR) reporter genes, a significant reduction of the Slug-WT3’UTR but not the Slug-Mut$^{363}$3’UTR activity was detected in LAPC4-KD (Fig. 6B) and RWPE1-KD cells (Additional file 6C).

Slug/SNAI2 is able to suppress the expression of epithelial marker such as E-Cadherin. As expected, an elevation of E-cadherin mRNA and protein was observed in miR-363 overexpressing LAPC4-KD (Fig. 6C) and RWPE1-KD cells (Additional file 6D). In contrast, the expression of both mRNA and protein levels of Vimentin, a mesenchymal marker, were suppressed in both cell lines compared to their controls (Fig. 6C and Additional file 6D). Functionally, miR-363 significantly reduced cell migration in both miR-363 expressing LAPC4-KD (Fig. 6D) and RWPE1-KD cells (Additional file 6E). We also noticed that cells collected from the lower chamber of Transwell exhibited lower miR-363 levels than the upper chamber (Fig. 6D). In contrast, knocking down of miR-363 by an antagonir (Anti-miR-363) enhanced the cell migration of C4-2D2 and RWPE1-Con cells (Additional file 6F). We further confirmed Slug/SNAI2 as the key target gene of miR-363-inhibited EMT, by restoring Slug/SNAI2 level in miR-363-expressing cells that resulted in a dose-dependent reduction of E-Cadherin mRNA and protein levels in both LAPC4-KD (Fig. 6E) and RWPE1-KD cells (Additional file 6G). On the other hand, a dose-dependent elevation of Vimentin mRNA and protein levels was also observed (Fig. 6E and Additional file 6G). Given that the stability of mature miR-363 is dependent on its 5’-end overhang structure, we examined the effect of SS$^6$Mut or DSMut pre-miR-363 on EMT and found the significant effects of DSMut on inhibiting the expression of Slug/SNAI2 and Vimentin mRNA and enhancing the mRNA expression of E-cadherin (Fig. 6F), which resulted in diminishing both cell migration and invasion (Fig. 6G).

The effect of IFIT5 on EMT. To gain more insights whether IFIT5 is able to facilitate EMT via increasing miR-363 turnover, we transfected IFIT5 expression vector in LAPC4-Con cells that express low level of IFIT5. The data clearly showed a significant elevation of Slug/SNAI2 and Vimentin expression along with the suppression of E-cadherin gene expression in IFIT5-expressing cells (Fig. 7A). Ectopic expression of IFIT5 in LAPC4-Con cells was able to alternate E-cadherin, Vimentin and Slug protein levels in a dose-dependent manner (Additional file 6H).
Moreover, we also observed the morphological change from a cuboidal epithelium-like to an elongated fibroblast-like shape in LAPC4-Con cell (Additional file 6I). On the other hand, knocking down IFIT5 in LAPC4-KD cells significantly increased E-cadherin expression and decreased the expression of both Slug/SNAI2 and Vimentin (Fig. 7B), which led to the reduction of cell motility in LAPC4-KD cells (Fig. 7C). In addition to prostate cell lines, the effect of both IFIT5 and miR-363 on cancer metastasis is also examined in several other cancer cell lines. We observed a significantly lower level of miR-363 in HepG2, 293T and 786O cell lines, which express relatively higher level of IFIT5 protein compared to LAPC4-Con cells (Additional file 7A). Knocking down of IFIT5 in these cell lines result in a significant elevation of mature miR-363 level (Additional file 7B). In the absence of IFIT5, E-cadherin was further upregulated and both Vimentin and slug were downregulated at mRNA and protein level (Fig. 7D, 7F and 7H), which led to reduced cell motility in all three cell lines (Fig. 7E, 7G and 7I). On the other hand, the outcome of overexpressing miR-363 in HepG2, 293T and 786O cell lines (Additional file 7C) was similar to that of IFIT5 knockdown (Additional file 7D-7J). This data imply that IFIT5 may elicit a global oncogenic impact in cancer via regulating EMT-targeting miRNAs. We further demonstrated that IFIT5-elicited EMT is mediated through miR-363 turnover (Fig. 7J and 7K) and XRN1 is a key component in the IFIT5 degradation machinery (Fig. 7L).

**The clinical correlation of IFIT5.** In general, high-grade PCa is associated with disease progression and poor clinical outcome. We therefore investigated the status of IFIT5 or miR-363 in different grades of PCa specimens. Our data (Fig. 8A) indicated that IFIT5 mRNA levels were significantly elevated in the high-grade PCa (G9), compared to both benign and low-grade (G6) tumors, in contrast, the pattern of miR-363 mRNA levels was opposite to that of IFIT5 (Fig. 8B); there appeared to be an inverse correlation between the expression of both genes (Fig. 8C). Meanwhile, both miR-92a-2 and miR-19b-2, immediately adjacent to miR-363, exhibited an elevation pattern in PCa tissues compared with benign tissues (Additional file 8A, 8B), implying a differential regulation or function associated with these miRNAs as compared to miR-363 in PCa. In addition, analyses from TCGA PCa dataset provided further support of our clinical observations; there are the positive correlation between IFIT5 and XRN1 (Additional file 8C) or Slug/SNAI2 or Vimentin (Fig. 8D) and the negative correlation between XRN1 and DAB2IP (Additional file 8D).
The differential regulation of miRNA cluster. In general, miRNA synthesis including miRNA cluster is under the control of single promoter similar to cellular genes [24, 25]. For example, the presence of two miR-17-92 cluster paralogs including miR-106b-25 and miR-106a-363 in mammals might be due to gene duplication [26]. MiR-17-92 is characterized as an onco-miR cluster from a variety types of cancers such as colon cancer [27, 28], Ewing Sarcoma [4], lung cancer [29, 30] and Burkitt’s lymphoma [31]. The pleiotropic functions of miR-17-92 cluster are: promoting proliferation, inhibiting apoptosis, increasing angiogenesis, and maintaining cell survival. In contrast, miR-106a-363 cluster contains 5 miRNAs (miR-106a, miR-18b, miR-20b, miR-19b, miR-92a-2) similar to the oncogenic miR-17-92 cluster plus one additional miR-363 that doesn’t have a miRNA homolog in miR-17-92 cluster. Our data not only demonstrate the tumor suppressive function of miR-363 in targeting Slug/SNAI2-mediated EMT in several cancer types but also unveil a unique regulation of miRNA cluster via degradation machinery. All together, this study provides not only a new knowledge of miRNA biogenesis but also a potential application of miR-363 as a therapeutic agent in preventing cancer progression.
CONCLUSIONS

In this study, we identify the tumor suppressive effect of miR-363, from a cluster that contains the rest of miRNAs characterized as onco-miRs, on intervening EMT. Most interestingly, a miRNA degradation machinery associated with IFIT5 that specifically recognizes a unique 5’-end structure of miRNA and recruits exoribonuclease (XRN1) to degrade this miRNA is delineated in this study, which could provide a new aspect of miRNA biogenesis for other miRNA genes (Fig. 8E). Meanwhile, we also dissect the tumor suppressive function of miR-363 in preventing EMT by targeting SNAI2/Slug in PCa. Overall, our finding delineates a new mechanism of miRNA turnover machinery specific for the degradation of a tumor suppressive miRNA derived from a cluster containing oncogenic miRNAs. We believe that this machinery can also work on other tumor suppressor miRNAs as well.
METHODS

Cell lines, Clinical specimens, and Plasmid constructs

Stable DAB2IP knockdown (KD) and control (Con) cells were generated from RWPE-1, PC-3 and LAPC4 cell lines using shRNA [16]. LAPC4 derived from PCa patients with lymph node metastasis was maintained in Iscove Dulbecco’s Modified Eagle’s Medium (Invitrogen) containing 10% fetal bovine serum (FBS). RWPE-1 derived from normal prostate epithelial cells immortalized with human papillomavirus 18 was maintained in Keratinocyte medium (Invitrogen) containing 10% FBS. The androgen-sensitive LNCaP cell line derived from PCa patients with lymph node metastasis was maintained in RPMI-1640 medium (Invitrogen) containing 10% FBS. C4-2 and PC-3, androgen-independent lines, were maintained in RPMI-1640 medium containing 10% FBS.

A total of 41 PCa specimens obtained from UT Southwestern Tissue Bank. All the specimens were collected from 6-mm core punch from radical prostatectomy and each punch was divided in half for snap-freeze and paraffin embedding then examined by pathologist to evaluate tumor grade. The Institutional Review Board of UT Southwestern approved the tissue procurement protocol for this study, and appropriate informed consent was obtained from all patients.

All the plasmid constructs are described in Supplemental information.

Plasmid or siRNA transfection

Cells (2.5x10^5) were seeded in 60-mm dish at 60-70% confluence before transfection. According to manufacturer’s protocol, transfection of plasmids was using either Xfect Reagent (Clontech) or EZ Plex transfection reagent (EZPLEX), and transfection of siRNA was using Lipofectamine® RNAiMAX reagent (Life Technology). Transient transfection was carried out 48 hrs post-transfection to harvest cell for further analyses. In addition, the stable clones (CL) were established after 2 weeks in the selective medium.

RNA isolation and quantitative real-time RT-PCR (qRT-PCR)

Small and large RNA were isolated and purified using mirVana miRNA Isolation Kit (Life Technologies). Small RNA (250 ng) was subjected to miScript II RT kit (QIAGEN) then 2.5 µl
cDNA was applied to a 25-μL reaction volume using miScript SYBR Green PCR kit (QIAGEN) in iCycler thermal cycler (Bio-Rad). All primer sequences are listed in Additional file 10, Table 2. The relative expression levels of precursor and matured miRNAs from each sample were determined by normalizing to SNORD95 small RNA. Large RNA (2 μg) was subjected to SuperScript VILO cDNA synthesis kit (Invitrogen) then 2.5 μl cDNA was applied to 25-μl reaction volume using SYBR Green ER qPCR SuperMix (Invitrogen). The relative expression levels of DAB2IP, IFIT5, E-cadherin, and Vimentin, and Slug/SNAI2 mRNA from each sample were determined by normalizing to 18S mRNA.

**Western blot analysis**
Cells were washed with PBS and lysed in lysis buffer [50mMTris-HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM sodium pyrophosphate, 10 mg/mL, aprotinin, 10 mg/mL leupeptin, 2 mM phenylmethylsulfonyl fluoride, and 1 mM EDTA] for 60 mins on ice. Cell lysates were spin down at 20,000 xg for 20 mins at 4°C. Protein extracts were subjected to SDS-PAGE using Bolt 4-12% Bis-Tris Plus gel (Invitrogen), and transferred to nitrocellulose membrane using Trans-Blot Turbo Transfer system (BIORAD). Membranes were incubated with primary antibodies against DAB2IP, E-Cadherin, Vimentin, Slug/SNAI2, XRN1, IFIT5 and Flag at 4 °C for 16-18 hrs, and horseradish peroxidase-conjugated secondary antibodies at room temperature for 1.5 hrs. Results were visualized with ECL chemiluminescent detection system (Pierce ThermoScientific). The relative protein expression level in each sample was normalized to actin or GAPDH.

**Immunoprecipitation (IP) assay**
Cells were harvested and protein lysates were prepared freshly before performing IP assay. Flag antibody (Sigma) or XRN1 antibody (AbCam) was incubated with 50 μl of Dynabeads® protein G (Novex, Life Technology) at room temperature for 15 mins. Subsequently, total 300 μg of protein lysate was incubated with the Dynabead-conjugated antibody at 4°C for 16-18 hrs. After washing, the eluates were subjected to SDS-PAGE using Bolt 4-12% Bis-Tris Plus gel (Invitrogen), and transferred to a nitrocellulose membrane using Trans-Blot Turbo Transfer system (BIORAD). Membranes were then subjected to western blot probed with different antibodies.
Luciferase reporter assay

Cells (8X10^4) were seeded onto 12-well plates at 75% confluence before transfection. pCMV-miR-363 plasmid was co-transfected with psiCHECK2-Slug3’UTR-WT or psiCHECK2-Slug3’UTR-Mut^363 plasmid into LAPC4-KD and RWPE-1-KD cells using Xfect Reagent (Clontech). Cells were harvested and lysed with Passive Lysis buffer (Promega) at 48 hrs after transfection. Luciferase activity was measured using the Dual-luciferase reporter assay (Promega) on the Veritas Microplate Luminometer (Turner Biosystems). Results were expressed as the relative light unit by normalizing the firefly luciferase activity with Renilla luciferase activity. Each experiment was performed in triplicates.

In vitro transcription of precursor miRNA

The PCR-amplified DNA fragment of T7-promoter-precursor-miRNAs was separated by 2% agarose gel electrophoresis and purified using Mermaid SPIN kit (MP Biomedicals), then subjected to in vitro transcription assay using T7 High Yield RNA synthesis kit (New England Biolabs). DNA template (750 ng) was mixed with T7 High Yield 10X buffer, NTP mixture (ATP, GTP, CTP and UTP), and T7 RNA polymerase then incubated at 37°C for 16 hrs. The precursor miRNA molecules was first treated with DNase I for 15 mins at 25° C and purified by acid phenol-chloroform extraction and ethanol precipitation. The molecular size and sequence of each purified precursor miRNA was confirmed by gel electrophoresis and qRT-PCR respectively.

RNA pull-down assay

The in vitro transcribed precursor miRNA was subjected to RNA pull down assay using Pierce Magnetic RNA-Protein Pull-Down Kit (ThermoScientific). An approximate 100 pmol of precursor miRNA were incubated with 10X RNA Ligase reaction buffer, RNase inhibitor, Biotinylated Cytidine Bisphosphate, and T4 RNA ligase at 16°C for 16 hrs. The biotinylated precursor miRNA was then purified and incubated with streptavidin magnetic beads for 30 mins at room temperature. Whole cell lysates were freshly prepared immediately before RNA pull-down assay and 200 μg of protein extract was mixed with the biotinylated precursor miRNA conjugated to streptavidin magnetic beads and incubated at 4°C for 1 hr. The magnetic beads
were washed 4 times before elution. Proteins associated with precursor miRNA were eluted and subjected to SDS-PAGE using Bolt 4-12% Bis-Tris Plus gel. Gel bands were stained with Coomassie blue and subjected to LC-MS/MS analysis.

**In vitro pre-miRNA degradation assay**

The *in vitro* transcribed precursor miRNAs were incubated with immunoprecipitated IFIT5 or XRN1 in the elution buffer at 37°C on a thermomixer (Eppendorf), then the RNA-containing buffer were collected at indicated time points and subjected to 15% TBE-Urea gel electrophoresis. To quantify the degradation of precursor miRNA, the 15% TBE-Urea gel was then stained with GelRed™ Nucleic Acid Gel Stains (VWR) and visualized under UV light in the AlphaImager devise (Protein Simple). The RNA bands were quantified by Multiplex band analysis (AlphaView Software) and the rate of degradation was calculated from each time point normalized to time zero.

**In vitro Transwell migration and invasion assay**

Cells (1X10^5 or 4X10^4) were seeded in the serum-free medium in the upper chamber of 6-well insert or 24-well insert with 8-μm pore size (Corning) with or without Matrigel coating for invasion or migration assay, respectively, while lower chamber contained medium supplemented with 10%FBS. After 2 days, cells that had transmigrated to the lower chamber were fixed by 4% paraformaldehyde and visualized under microscope. Quantification of transmigrated cells was carried out with crystal violet staining and measurement at OD_{555nm}. Each experiment was performed in triplicates.

**Statistics analysis**

Statistics analysis was performed by using GraphPad Prism software. Statistical significance was evaluated using Student t-test. P<0.05 was considered a significant difference between compared groups and marked with an asterisk. The statistical association between miR-363 and IFIT5 expression among different grades of human PCa was evaluated with regression correlation analysis.
**Abbreviations**

CRPC  castration resistant prostate cancer

EMT  epithelial–mesenchymal transition

IFIT5  Interferon-induced protein with tetratricopeptide repeats 5

KD  knock-down

miRNA  microRNA

PCa  prostate cancer

shRNA  small hairpin RNA

tRNA  transfer RNA

Vec  Vector

WT  wild type

XRN1  exoribonuclease
Competing interests

There are no competing interests.
AUTHORS’ CONTRIBUTIONS

UGL designed and performed experiments and drafted the manuscript. RCP, DY LG, JCZ, and SFT constructed plasmid vectors, performed experiments and processing clinical tissues. All authors contributed to the interpretation of the data. UGL and JTH conceived of the study, participated in its design and coordination, and contributed to data analysis. All of the authors approved this manuscript.
DESCRIPTION OF ADDITIONAL DATA

Additional file 1

(A) Profile of miRNA expression in RWPE1-KD cells compared with RWPE1-Con cells. (B) Relative fold change of each miRNA from microarray screening (green and red indicate decreased and increased fold change in RWPE1-KD cells after normalizing with RWPE1-Con cells, respectively). (C) The expression levels of mature miR-363 in DAB2IP-KD renal cell lines (786-O and HK2) after normalizing with the vector control (Con). (D) Induction of mature miR-363 by ectopic expression of DAB2IP in HEK293 cells. (E) Expression levels of precursor and mature miRNAs (miR-106a, iR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in DAB2IP-expressing HEK293D cells after normalizing with HEK293 cells.

Additional file 2

(A) Relative change of IFIT5 mRNA and protein level in pairs of DAB2IP-positive and – negative prostate cells (LAPC4, RWPE1 and C4-2). (B-C) Suppression of IFIT5 protein expression by ectopic expression of DAB2IP in LNCaP and HEK293 cell lines after normalizing with the control vector (Vec). (D) Induction of mature miR-363 in LAPC4-KD cells transfected with IFIT5 siRNA compared with control siRNA (Con). (E) Induction of mature miR-363 in LAPC4-KD and RWPE1-KD cells by IFIT5 siRNA after normalizing with the control siRNA (Con). (F) Expression levels of mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in IFIT5-KD (siRNA-IFIT5+/+) LNCaP cells compared with the control siRNA (siRNA-Con/-). (G) Expression levels of precursor miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in IFIT5-KD (siRNA-IFIT5) LAPC4-KD, C4-2Neo, RWPE1-KD and LNCaP cells after normalizing with the control siRNA (siRNA-Con).
Additional file 3

(A) Left panel: Gel electrophoresis of pre-miR-363 fragment after incubation with IFIT5 protein (IP) or elution buffer at 37°C. Middle panel: Time-dependent change of pre-miR-363 degradation normalized with 0 min. Right panel: IP of IFIT5 protein subjected to in vitro RNA degradation assay. (B) Expression levels of primary, precursor and mature miR-363 in RWPE1-KD cells transfected with native, SS\textsuperscript{6} Mut or DSMut pre-miR-363 plasmids for 24 hrs and normalized with the control vector (Vec). (C) Time-dependent change of degraded pre-miR-92a-2 and SS\textsuperscript{1} Mut pre-miR-92a-2 after incubating with IFIT5 protein complex at 37°C normalized with 0 min. (*P<0.05). (D) Time-dependent change of degraded pre-miR-18b and SS\textsuperscript{2} Mut pre-miR-18b after incubating with IFIT5 protein complex at 37°C normalized with 0 min. (*P<0.05).

Additional file 4

(A) Relative expression level of XRN1 protein in DAB2IP-positive and -negative cells (LAPC4, RWPE1, C4-2, and HK2). (B) Suppression of XRN1 protein expression by ectopic expression of DAB2IP in LNCaP, RWPE1-KD, and HK2-KD cells and compared with the control vector (Vec). (C) Induction of miR-363 expression in LAPC4-KD cells transfected with XRN1 siRNA and compared with the control siRNA (Con). (D) Left panel: IP of endogenous XRN1 protein subjected to in vitro RNA degradation assay. Right panel: Time-dependent change of native, SS\textsuperscript{6} Mut and DSMut pre-miR-363 degradation (bracket) after incubation with XRN1 protein at 37°C, each time point was normalized with 0 min. (E) Left panel: Western blot from Vector or IFIT5-transfected LAPC4-Con cells. Right panel: Time-dependent change of degraded SS\textsuperscript{6} Mut pre-miR-363 fragments in the presence of XRN1 alone (XRN1+Vector) or XRN1-IFIT5 complex (XRN1+IFIT5) at 37°C. (F) Left panel: western blot from IFIT5-expressing LAPC4-
Con cells transfected with control or XRN1 siRNA. Right panel: Time-dependent change of degraded SS$^6$Mut pre-miR-363 fragments in the presence of XRN1-IFIT5 complex derived from IFIT5 w/ siRNA-Con or IFIT5 w/ siRNA-XRN1 at 37°C.

**Additional file 5**

(A) Relative expression level of mature miR-363 in RWPE1-Con cells transfected with wild type (WT) and mutant (Δ7-8, K422A) IFIT5 after normalizing with the control vector. (B) Interaction between pre-miR-363 and wild type (WT) or mutant IFIT5 (Δ7-8, K415A, K422A) derived from RWPE1-Con cells using RNA pull down. (C) The effect of pre-miR-92a-2 molecule on the interaction between XRN1 and IFIT5 using IP with Flag antibodies.

**Additional file 6**

(A) Reduction of Slug/SNAI2 mRNA and protein levels in miR-363-expressing RWPE1-KD cells after normalizing with the control vector (Vec). (*p<0.05, CL: miR-363 expressing stable clone) (B) Predicted sequence of the putative miR-363 target site in 3’UTR of Slug/SNAI2 mRNA (Slug-WT 3’UT) and its mutant sequence (Slug Mut$^{363}$ 3’UTR). (C) Luciferase reporter activities in RWPE1-KD cells co-transfected with siCHECK2-slug-WT 3’UTR or -slug-Mut$^{363}$ 3’UTR and pCMV-miR363 or control vector (Vec). (RFU=Renilla to Firefly luciferase activity, each bar represents mean ± SD of four replicated experiments.) (D) Expression levels of E-cadherin or Vimentin mRNA and protein in miR-363-expressing RWPE1-KD clones. (E) Cell migration of RWPE1-Con, -KD and miR363-expressing RWPE1-KD clones. (F) Cell migration of RWPE1-Con and C4-2D2 cells transfected with anti-miR-363. Cells transmigrated at the lower chamber were stained with crystal violet and quantified at OD 555nm. Each bar represents
mean ± SD of three replicated experiments. (*P<0.05) (G) The effect of Slug on the expression levels of E-cadherin and Vimentin mRNA and protein in miR-363-expressing RWPE1-KD clones (CL2) after normalizing with the control vector (Con). (*P<0.05). (H) The dose-dependent effect of IFIT5 on the protein levels of E-Cadherin, Vimentin and Slug in LAPC4-Con cells. (I) The effect of IFIT5 on morphological change in LAPC4-Con cells compared with the control vector (Vec).

Additional file 7

(A) The expression level of miR-363 and IFIT5 protein among prostate (LAPC4), brain (U118), kidney (786O, 293T) and liver (HepG2) cancer cell lines. (B) Induction of mature miR-363 levels in IFIT5-shRNA knockdown (sh-IFIT5, +) HepG2, 293T and 786O cell lines, compared to the control shRNA (-). (C, E, G) Overexpression of miR-363 and its impact on the mRNA level of E-cadherin, Slug and Vimentin in HepG2 (C), 293T (E) and 786O cell lines (G), compared to control vector (Vec). (D) Transwell migration of miR-363 expressing HepG2 cells (363), compared to the control vector (Vec). (F) Transwell invasion of miR-363 expressing 293T cells (363), compared to the control vector (Vec). (H) Transwell invasion of miR-363 expressing 786O cells (363), compared to the control vector (Vec). Migrated or invaded cells at the lower chamber were stained with crystal violet and quantified at OD 555nm. Each bar represents mean ± SD of three replicated experiments (* p<0.05).  

Additional file 8

(A, B) Expression levels of mature miR-92a-2 and miR-19b-2 in human prostate specimens including benign (N=10), G6 (N=9), G7(N=9), G8(N=6) and G9(N=7) (*p<0.05, **p<0.0001).
(C,D) Clinical correlation between IFIT5 and XRN1, as well as XRN1 and DAB2IP mRNA level in PCa from TCGA PCa dataset.

**Additional file 9**

List of protein candidates derived from Mass Spectrometry after using precursor miR-363 to pull down protein complex in a variety of pairs (LAPC4, RWPE1 and C4-2) with or without DAB2IP expression.

**Additional file 10**

Primers designed for site-directed mutagenesis and PCR.
ACKNOWLEDGMENTS

We thank Dr. Collins (University of California, Berkeley) for providing IFIT5 cDNA constructs, Dr. Dong (Emory University, Atlanta) for providing the psiCHECK2-Slug3’UTR plasmid. Drs. Kou-Juey Wu (China Medical University, Taichung, Taiwan) and Dr. Vimal Selvaraj (Cornell University, Ithaca) for the helpful discussion. This work was supported by grants from the United States Army (W81XWH-11-1-0491 to JTH) and (W81XWH-14-1-0249 to UGL)
REFERENCES


Figure Legends

**Figure 1. The effect DAB2IP on miR-363 expression in prostate cell lines.** (A) Expression levels of miR-363 in DAB2IP-knockdown (KD) prostate cell lines after normalizing with the control (Con). (B) Induction of miR-363 by ectopic expression of DAB2IP in C4-2Neo and LAPC4-KD cell lines after normalizing with the control vector (Vec). (C) Expression levels of primary miR-106a-363 in DAB2IP-positive and -negative sublines. (D) Expression levels of precursor miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in DAB2IP-positive and-negative cells. (E) Expression levels of mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in DAB2IP-positive and-negative cells.

**Figure 2. The impact of IFIT5 on miR-363 maturation from the miR-106a-363 cluster.** (A) The interaction between IFIT5 protein and pre-miR-363 in DAB2IP-positive and -negative cells using RNA pull down assay. (B-C) Suppression of IFIT5 protein expression by ectopic transfecting DAB2IP into LAPC4-KD and C4-2Neo cells after normalizing with the control vector (Vec). (D-F) Expression levels of mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in IFIT5-expressing (IFIT5) LAPC4-Con, C4-2D2 and RWPE1-Con cells after normalizing with the control vector (Vec). (G-I) Expression levels of mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in IFIT5-siRNA knockdown (+) LAPC4-KD, C4-2Neo and RWPE1-KD cells compared to the control siRNA (-).

**Figure 3. IFIT5-mediated precursor miR-363 degradation in vitro.** (A) Time-dependent change of degraded pre-miR-92a-2 and pre-miR-363 fragments (bracket) after incubation with
IFIT5 protein complex at 37°C normalized with 0 min. (*P<0.05) (B) Left panel: Mutation of nucleotides (red box) for generating 5’-end 6 nucleotides single stranded pre-miR-363 (SS\textsuperscript{6}Mut pre-miR-363) and blunt 5’-end double stranded pre-miR-363 (DSMut pre-miR-363). Both mature miR-363 and miR-363* sequence are shown in pink. Right panel: Expression levels of primary, precursor and mature miR-363 in LAPC4-KD cells transfected with Native, SS\textsuperscript{6} Mut or DSMut pre-miR-363 plasmids for 24 hrs after normalizing with the vector control. (C) Time-dependent change of degraded native, SS\textsuperscript{6} Mut and DSMut pre-miR-363 fragments (bracket) after incubation with IFIT5 protein at 37°C, each time point was normalized with 0 min. (*p<0.05) (D) Induction of mature miR-363 in cells transfected with SS\textsuperscript{6} Mut pre-miR-363 or DSMut pre-miR-363 plasmids and IFIT5 siRNA after normalizing with the control vector (Vec). (Con=control siRNA). (E) Interaction between IFIT5 protein and SS\textsuperscript{6} Mut or DSMut pre-miR-363 RNA molecules using RNA pull down assay. (F) Upper panel: predicted structure and sequence of pre-miR-92a-2. Middle panel: mutation of nucleotides (red box) for generating single nucleotide overhanging structure of pre-miR-92a-2 (SS\textsuperscript{1}Mut). Lower panel: interaction between IFIT5 protein and pre-miR-92a-2 or SS\textsuperscript{1}Mut pre-miR-92a-2 RNA molecules using RNA pull down assay. (G) Upper panel: predicted structure and sequence of pre-miR-18b. Middle panel: mutation of nucleotides (red box) for generating double nucleotides overhanging structure of pre-miR-18b (SS\textsuperscript{2}Mut). Lower panel: Interaction between IFIT5 protein and pre-miR-18b or SS\textsuperscript{2}Mut pre-miR-18b RNA molecules using RNA pull down assay.

Figure 4. Interaction between XRN1 with IFIT5 leading to pre-miR-363 degradation \textit{in vitro}. (A) Interaction between IFIT5 and XRN1 proteins using IP by Flag and XRN1 antibodies,
respectively. **(B)** Suppression of XRN1 protein expression by ectopic transfecting DAB2IP into LAPC4-KD and C4-2Neo cells after normalizing with the control vector (Vec). **(C)** Induction of mature miR-363 in LAPC4-KD cells transfected with XRN1 siRNA after normalizing with the control siRNA (Con). **(D)** Expression levels of precursor and mature miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2 and miR-363) in XRN1-KD (siRNA-XRN1) LAPC4-KD cells after normalizing with the control siRNA (siRNA-Con). **(E)** Time-dependent change of degraded native, SS\(^6\)Mut and DSMut pre-miR-363 fragments after incubation with XRN1 protein at 37°C after normalizing with 0 min. (*p<0.05) **(F)** Time-dependent change of degraded SS\(^6\)Mut pre-miR-363 fragments after incubation with immunoprecipitated-XRN1 alone (XRN1+Vec) or XRN1-IFIT5 complex (XRN1+IFIT5) at 37°C after normalizing with 0 min. (*p<0.05) **(G)** Time-dependent change of degraded SS\(^6\)Mut pre-miR-363 after incubation with the immunocomplex derived from cells transfected with IFIT5 and control siRNA (IFIT5 w/siRNA-Con) or XRN1 siRNA (IFIT5 w/siRNA-XRN1) at 37°C after normalizing with 0 min. (*p<0.05) **(H)** Dose-dependent recovery of mature miR-363 expression in IFIT5-expressing LAPC4-Con cells transfected with XRN1 siRNA after normalizing with the control vector (Con: control siRNA, *p<0.05).

**Figure 5.** The C-terminal TPR 7-8 domain of IFIT5 required for the interaction with pre-miR-363 and XRN1. **(A)** Relative expression level of mature miR-363 in LAPC4-Con and C4-2D2 cells transfected with wild type (WT) and mutant (\(\Delta\)7-8, K415A, K422A) IFIT5 after normalizing with the control vector. **(B)** Interaction between pre-miR-363 RNA molecule and wild type (WT) or mutant IFIT5 (\(\Delta\)7-8, K415A, K422A) proteins derived from LAPC4-Con (Upper panel) or C4-2D2 (lower panel) cells using RNA pull down assay. **(C)** Interaction
between XRN1 and wild type (WT) or Δ7-8 mutant IFIT5 derived from LAPC4-Con cells using IP. (D) The effect of SS^6 Mut (upper panel) or DSMut pre-miR-363 RNA molecule (lower panel) on the protein-protein interaction between XRN1 and IFIT5 using IP with Flag antibodies.

**Figure 6. The effect of miR-363 and IFIT5 on EMT in LAPC4 cells.** (A) Reduction of Slug/SNAI2 mRNA levels in miR-363-expressing LAPC4-KD cells after normalizing with the control vector (Vec). (*p<0.05, CL: miR-363 expressing stable clone) (B) Luciferase reporter activities in LAPC4-KD cells co-transfected with siCHECK2-Slug-WT 3’UTR or Slug Mut^363 3’UTR and pcMV-miR363 or control vector. (RFU=Renilla to Firefly luciferase activity, each bar represents mean ± SD of four replicated experiments. * p<0.05) (C) Expression levels of E-cadherin and Vimentin mRNA and protein in miR-363-expressing LAPC4-KD cell. (D) The effect of miR-363 on cell migration of GFP-expressing LAPC4-KD cells. GFP-positive cells were observed under microscope and migrated cells were stained with crystal violet and quantified at O.D. 555nm. (Each bar represents mean ± SD of three replicated experiments. * p<0.05). (E) The effect of Slug on the expression levels of E-cadherin and Vimentin mRNA and protein in miR-363-expressing LAPC4-KD cells (CL3) after normalizing with the control vector (Con). (*P<0.05). (F) The effect of SS^6 Mut and DSMut pre-miR-363 on the expression levels of mature miR-363, E-cadherin, Vimentin and Slug mRNA in LAPC4-KD cells after normalizing with the control vector. (G) The effect of SS^6 Mut or DSMut pre-miR-363 on cell migration or invasion in LAPC4-KD cells. Migrated cells were stained with crystal violet and quantified at OD 555nm. Each bar represents mean ± SD of three replicated experiments. (* p<0.05, NS=no significance)
Figure 7. The impact of IFIT5 on EMT in liver and kidney cancer cell lines. (A) The effect of IFIT5 on the expression levels of E-Cadherin, Vimentin and Slug mRNA and protein in LAPC4-Con cells after normalizing with the control vector (Vec). (B) Expression levels of E-Cadherin, Vimentin and Slug mRNA and proteins in LAPC4-KD cells transfected with IFIT5 siRNA (+) compared to the control siRNA (-). (C) Cell invasion assay of LAPC4-KD cells transfected with IFIT5 siRNA (+) compared to the control siRNA (-). (D, F, H) The expression level of E-cadherin, Slug and Vimentin mRNA in IFIT5-shRNA knockdown (+) HepG2 (D), 293T (F) and 786O cells (H), compared to the control shRNA (-). (E) Transwell migration of IFIT5-knockdown (+) HepG2 cells, compared to the control shRNA (-). (G) Transwell migration of IFIT5-knockdown (+) 293T cells, compared to the control shRNA (-). (I) Transwell invasion of IFIT5-knockdown (+) 786O cells, compared to the control shRNA (-). Migrated or invaded cells at the lower chamber were stained with crystal violet and quantified at OD 555nm. Each bar represents mean ± SD of three replicated experiments (* p<0.05). (J) The impact of IFIT5 on miR-363 maturation in LAPC4-KD cells transfected with SS6Mut or DSMut pre-miR-363 plasmids. Each bar represents mean ± SD of three replicated experiments. (* p<0.05). (K) The effect of IFIT5 and SS6Mut or DSMut pre-miR-363 on cell invasion of LAPC4-KD cells. Invaded cells at the lower chamber were stained with crystal violet and quantified at OD 555nm. Each bar represents mean ± SD of three replicated experiments. (* p<0.05). (L) The effect of XRN1 on the expression levels of E-cadherin, Vimentin and slug protein in IFIT5-expressing LAPC4-Con cells after normalizing with the control vector (Vec) (Con: control siRNA).

Figure 8. The effect of IFIT5-mediated miR-363 degradation on EMT and its clinical correlation in PCa. (A, B) Relative induction of IFIT5 mRNA and mature miR-363 level in
human PCa specimens derived from different grades including benign (N=10), G6 (N=9),
G7(N=9), G8(N=6) and G9(N=7) (*p<0.05, **p<0.0001). (C) Clinical correlation between miR-
363 and IFIT5 mRNA expression in human PCa specimens graded from G6 to G9 (N=31, R=-
0.3183, p=0.0405). (D) Clinical correlation between IFIT5 and SNAI2/Slug or Vimentin in PCa
from TCGA PCa dataset. (E) Schematic representation of IFIT5-mediated pre-miR-363 turnover
leading to EMT in cancer.
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.

A, B, C: mRNA fold of induction

D, E, F, G, H, I: E-Cadherin, Vimentin, Slug

J, K, L: miR-363 fold of induction, Relative cell number (O.D. 555nm), Western blotting
Figure 8.

(A) IFIT5 mRNA fold of induction

(B) mIR-363 fold of induction

(C) mIR363 fold induction vs. IFIT5 mRNA fold induction

(D) SMA2 vs. IFIT5

(E) Schematic diagram of the regulation of Slug by IFIT5 and mIR-363.
Additional file 1

MicroRNA microarray: RWPE1-KD vs. RWPE1-Con

A

MicroRNA fold of induction

B

miR-363 fold of induction

C

miR-363 fold of induction

D

miR-363 fold of induction

E

miR-363 fold of induction

Additional file 1
Additional file 4

A

<table>
<thead>
<tr>
<th></th>
<th>LAPC4</th>
<th>RWPE1</th>
<th>C4-2</th>
<th>HK2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>XRN1</td>
<td>DAB2IP</td>
<td>GAPDH</td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>KD</td>
<td>1.27</td>
<td>1.48</td>
<td>1.36</td>
<td>2.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vec</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DAB2IP</td>
<td>GAPDH</td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>KD</td>
<td>0.45</td>
<td>0.33</td>
<td>0.27</td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>LNCap</th>
<th>RWPE1-KD</th>
<th>HK2-KD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>XRN1</td>
<td>DAB2IP</td>
<td>GAPDH</td>
</tr>
<tr>
<td>Con</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>KD</td>
<td>0.51</td>
<td>0.51</td>
<td>0.44</td>
</tr>
<tr>
<td>D2</td>
<td>Neo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>1.00</td>
<td>1.28</td>
<td>0.14</td>
</tr>
<tr>
<td>KD</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vec</td>
<td></td>
<td>DAB2IP</td>
<td>GAPDH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.14</td>
<td>0.05</td>
</tr>
</tbody>
</table>

C

mIR-363 fold of induction

D

Input 
Elute

XRN1
IGG XRN1
GAPDH

Native pre-miR-363
SSMut pre-miR-363
DSMut pre-miR-363

0 15 30 45 60 90 120 (min)

E

XRN1+Vec
XRN1+IFIT5

XRN1
IFIT5
Vec
IFIT5
GAPDH

0 30 60 90 120

F

IFIT5 w/siRNA-Con
IFIT5 w/siRNA-XRN1

XRN1
IFIT5
GAPDH

Con
XRNI
GAPDH

0 30 60 90 120
Additional file 5

A

B

C

Pre-miR-92a-2
Additional file 7

A. miR-363 level

B. miR-363 level

C. HepG2

D. Rel. cell number (O.D. 555nm)

E. 293T

F. Rel. cell number (O.D. 555nm)

G. 786O

H. Rel. cell number (O.D. 555nm)
Additional file 8
### Additional file 9

#### Table 1.
List of protein candidates derived from Mass Spectrometry after using precursor miR-363 to pull down protein complex in a variety of pairs (LAPC4, RWPE1 and C4-2) with or without DAB2IP expression.

<table>
<thead>
<tr>
<th>Cell line</th>
<th>DAB2IP-/DAB2IP+ Ratio</th>
<th>PSMs</th>
<th>Peptide Seqs</th>
<th>% Coverage</th>
<th>S. COUNTS</th>
<th>S. INDEX (MIC SIn)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DAB2IP+</td>
<td>DAB2IP-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LAPC4</td>
<td>RWPE1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C4-2</td>
<td>RWPE1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C4-2Neo</td>
<td>RWPE1</td>
</tr>
</tbody>
</table>

**IFIT5_HUMAN** Interferon-induced protein with tetratricopeptide repeats 5 OS=Homo sapiens GN=IFIT5 PE=1 SV=1
- LAPC4: 1.28
- RWPE1: 1.28
- C4-2: 1.28

**B9A067_HUMAN** Mitochondrial inner membrane protein OS=Homo sapiens GN=IMMT PE=2 SV=2
- LAPC4: 0.28
- RWPE1: 0.28
- C4-2: 0.28

**SNUT1_HUMAN** U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 PE=1 SV=1
- LAPC4: 0.31
- RWPE1: 0.31
- C4-2: 0.31

**ADT2_HUMAN** ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7
- LAPC4: 0.20
- RWPE1: 0.20
- C4-2: 0.20

**PARP1_HUMAN** Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4
- LAPC4: 0.35
- RWPE1: 0.35
- C4-2: 0.35

**XRCC5_HUMAN** X-ray repair cross-complementing protein 5 OS=Homo sapiens GN=XRCC5 PE=1 SV=3
- LAPC4: 0.20
- RWPE1: 0.20
- C4-2: 0.20

**SFPQ_HUMAN** Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ PE=1 SV=2
- LAPC4: 0.24
- RWPE1: 0.24
- C4-2: 0.24

**ATPA_HUMAN** ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 SV=1
- LAPC4: 0.15
- RWPE1: 0.15
- C4-2: 0.15

**VDAC2_HUMAN** Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens GN=VDAC2 PE=1 SV=2
- LAPC4: 0.12
- RWPE1: 0.12
- C4-2: 0.12

**H4_HUMAN** Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2
- LAPC4: 0.10
- RWPE1: 0.10
- C4-2: 0.10

**IFL2_HUMAN** Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=IFL2 PE=1 SV=2
- LAPC4: 0.11
- RWPE1: 0.11
- C4-2: 0.11

**ACACA_HUMAN** Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2
- LAPC4: 0.12
- RWPE1: 0.12
- C4-2: 0.12

**E3L1L3_HUMAN** Myb-binding protein 1A (Fragment) OS=Homo sapiens GN=MYBBP1A PE=4 SV=1
- LAPC4: 0.13
- RWPE1: 0.13
- C4-2: 0.13

**ILF2_HUMAN** Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2
- LAPC4: 0.14
- RWPE1: 0.14
- C4-2: 0.14

**ACACA_HUMAN** Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2
- LAPC4: 0.15
- RWPE1: 0.15
- C4-2: 0.15

**E3L1L3_HUMAN** Myb-binding protein 1A (Fragment) OS=Homo sapiens GN=MYBBP1A PE=4 SV=1
- LAPC4: 0.16
- RWPE1: 0.16
- C4-2: 0.16

**ILF2_HUMAN** Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2
- LAPC4: 0.17
- RWPE1: 0.17
- C4-2: 0.17

**ACACA_HUMAN** Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2
- LAPC4: 0.18
- RWPE1: 0.18
- C4-2: 0.18

**E3L1L3_HUMAN** Myb-binding protein 1A (Fragment) OS=Homo sapiens GN=MYBBP1A PE=4 SV=1
- LAPC4: 0.19
- RWPE1: 0.19
- C4-2: 0.19
### Primers used for site-directed mutagenesis:

<table>
<thead>
<tr>
<th>Primers used for site-directed mutagenesis:</th>
<th>Insertion of T7 promoter upstream to pre-miR-363 sequence in pCMV-miR-363 expression plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre363+T7m1-Forward</td>
<td>5'-AAGTTCTGATATTGTGTAATTGCGAATAGTCGCGCTTACTGTTTTCGTTGCCTG-3'</td>
</tr>
<tr>
<td>Pre363+T7m2-Reverse</td>
<td>5'-CGACACAGCAACACGCCACAGATATTGGCGATGACCTTTACGACGACTTTACG-3'</td>
</tr>
<tr>
<td>Pre363+T7m2-Forward</td>
<td>5'-TTGTCGTATTGTGTAATTGCGAATAGTCGCGCTTACTGTTTTCGTTGCCTG-3'</td>
</tr>
<tr>
<td>Pre363+T7m2-Reverse</td>
<td>5'-CGACACAGCAACACGCCACAGATATTGGCGATGACCTTTACGACGACTTTACG-3'</td>
</tr>
<tr>
<td>SDM_T7-363-DS-Forward</td>
<td>5'-GGCGAAATGATCTGTTTTGCGGTTTACGGGTGGATCAC-3'</td>
</tr>
<tr>
<td>SDM_T7-363-DS-Reverse</td>
<td>5'-GGCGAAATGATCTGTTTTGCGGTTTACGGGTGGATCAC-3'</td>
</tr>
<tr>
<td>SDM_T7-363-SS-Reverse</td>
<td>5'-GTGATCCACCCGACTTTGGAACAAACGACATCATTGTCG-3'</td>
</tr>
<tr>
<td>SDM_T7-363-SS-Reverse</td>
<td>5'-GTGATCCACCCGACTTTGGAACAAACGACATCATTGTCG-3'</td>
</tr>
<tr>
<td>SDM_T7-363-DS-Reverse</td>
<td>5'-GGCGAAATGATCTGTTTTGCGGTTTACGGGTGGATCAC-3'</td>
</tr>
<tr>
<td>SDM_T7-363-SS-Reverse</td>
<td>5'-GTGATCCACCCGACTTTGGAACAAACGACATCATTGTCG-3'</td>
</tr>
</tbody>
</table>

### Generating Mutant form of T7-pre-miR-363 DNA templates

<table>
<thead>
<tr>
<th>Primers used for site-directed mutagenesis:</th>
<th>Insertion of ApaI upstream to pre-miR-92a-2 sequence in pGEM-pre-92a-2 plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td>T7-Apa1-mut-Forward</td>
<td>5'-ATTCCGATTTCTGCGGCACGCTTTCCTCCACAGCGG-3'</td>
</tr>
<tr>
<td>T7-Apa1-mut-Reverse</td>
<td>5'-GGCTCTGCTGAAAGAAGCGGGCCCAAGAGATGACGAT-3'</td>
</tr>
</tbody>
</table>

### Generating mutant miR-363 target site in siCHECK2-Slug 3'UTR

<table>
<thead>
<tr>
<th>Primers used for site-directed mutagenesis:</th>
<th>Insertion of Nhe1 into pre-miR-92a-2 sequence in pCMV-miR-363 plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLUG-SDM-Forward</td>
<td>5'-ATTTTAATTATTGGAAATATTGCTATATTGCGCAGATTATTAAGGATTCTTAC-3'</td>
</tr>
<tr>
<td>SLUG-SDM-Reverse</td>
<td>5'-ATTTTAATTATTGGAAATATTGCTATATTGCGCAGATTATTAAGGATTCTTAC-3'</td>
</tr>
</tbody>
</table>

### Primers used for PCR:

<table>
<thead>
<tr>
<th>Primers used for PCR:</th>
<th>Generating Mutant form of SN-A/C pre-miR-92a-2 DNA template</th>
</tr>
</thead>
<tbody>
<tr>
<td>pre363wT7-Forward</td>
<td>5'-GTCATGGTAATAATACGAAGTCACTATGCATTTGATTCGCGACG-3'</td>
</tr>
<tr>
<td>pre363wT7-Reverse</td>
<td>5'-GGTTTACAGTGTACGGACG-3'</td>
</tr>
<tr>
<td>Pre92a-2-Forward</td>
<td>5'-GGCAGCTATCGGCGGATTTGATTCGCGACG-3'</td>
</tr>
<tr>
<td>Pre92a-2-Reverse</td>
<td>5'-GTCATGGTAATAATACGAAGTCACTATGCATTTGATTCGCGACG-3'</td>
</tr>
<tr>
<td>T7_pre92a-2-Forward</td>
<td>5'-GTCATGGTAATAATACGAAGTCACTATGCATTTGATTCGCGACG-3'</td>
</tr>
<tr>
<td>T7_pre92a-2-Reverse</td>
<td>5'-GTCATGGTAATAATACGAAGTCACTATGCATTTGATTCGCGACG-3'</td>
</tr>
<tr>
<td>SDM_T7-363-DS-Forward</td>
<td>5'-GGCGAAATGATCTGTTTTGCGGTTTACGGGTGGATCAC-3'</td>
</tr>
<tr>
<td>SDM_T7-363-SS-Forward</td>
<td>5'-GGCGAAATGATCTGTTTTGCGGTTTACGGGTGGATCAC-3'</td>
</tr>
</tbody>
</table>

### Generating Mutant form of SN-A/C pre-miR-92a-2 DNA template

<table>
<thead>
<tr>
<th>Primers used for PCR:</th>
<th>Generating Mutant form of SN-A/C pre-miR-92a-2 DNA template</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-92-5A-Fw</td>
<td>5'-ATTCCGATTTCTGCGGCACGCTTTCCTCCACAGCGG-3'</td>
</tr>
<tr>
<td>X-92-3C-Rv</td>
<td>5'-GGCTCTGCTGAAAGAAGCGGGCCCAAGAGATGACGATGACG-3'</td>
</tr>
</tbody>
</table>
The specific regulation of miR-363 turnover from miR-106a-363 cluster by IFIT5 complex leading to epithelial-to-mesenchymal transition

U-Ging Lo, Rey-Chen Pong, Diane Yang, Leah Gandee, Jiancheng Zhou, Shu-Fen Tseng, Jer-Tsong Hsieh

Department of Urology
University of Texas Southwestern Medical Center
Dallas, TX
I have no financial relationships to disclose.

I will not discuss off label use and/or investigational use in my presentation.
The mechanism of DAB2IP in cell homeostasis

- **Activation**
  - Cell proliferation, Cell survival
  - Cell apoptosis, autophagy
  - **Cell invasion or metastasis**
  - Stemness
  - Angiogenesis

- **Inhibition**
  - DAB2IP

**References**

- JBC, 277: 12622, 2002
- JCI, 11: 1933, 2003
- PNAS, 106: 19878, 2009
- PNAS, 107: 2485, 2010
- Cancer Res., 70: 2829, 2010
- Oncogene, 33: 1954, 2014
The positive correlation between DAB2IP and miR-363 expression
DAB2IP mediates a specific regulation of miR-363 from miR-106a-363 cluster

Resemble to miR-106a-363 in miRNA seed sequence
The impact of IFIT5 on miR-363 maturation distinct from miR-106a-363 cluster.
IFIT5 elicits miR-363 turnover at the precursor stage.
The role of XRN1 in IFIT5 complex in pre-miR-363 degradation

![Image of experiments and graphs](image.png)
The TPR 7-8 domain of IFIT5 is required for docking XRN1 on pre-miR-363

(Katibah et al., Cell 2012)
miR-363 can suppress EMT by targeting Slug in PCa
Clinical correlation of IFIT5 or miR-363 in PCa tissues
A differential expression profile of miR-363 from miR-106a-363 cluster is regulated by miRNA turnover.

The IFIT5-XRN1 complex is responsible for the specific miR-363 turnover.

The IFIT5 C’ terminal TPR7-8 domain is required for (1) interaction with 5’end of precursor miR-363 and (2) recruitment of XRN1.

DAB2IP play a critical role in regulating both IFIT5 and XRN1 expression.

miR-363 perform tumor suppressive function and prevent EMT by targeting Slug.

IFIT5 and miR-363 are inversely correlated in prostate cancer malignancies.
Acknowledgement

JT Hsieh Lab
Jer-Tsong Hsieh
Ray-Chen Pong
Eun-Jin Yun
Leah Gandee
Diane Yang
Jiancheng Zhou
Shu-Fen Tseng
Bin Wang
Cheng-Kuo Lai
Li-Chiung Lin
Chun-Jung Lin
Wai Chen
Elizabeth Hernandez
John Santoyo
The role of IFIT5 in miR-363 turnover

Short title: The function and regulation of miR-363

U-Ging Lo, Rey-Chen Pong, Diane Yang, Leah Gandee, Jiancheng Zhou, Shu-Fen Tseng, and Jer-Tsong Hsieh

Background: The majority of prostate cancer (PCa) mortality is due to the recurrent metastatic castration resistant PCa (mCRPC). The acquisition of epithelial-to-mesenchymal transition (EMT) in PCa cells increases their metastatic potential. Although several microRNAs (miRNAs) have been shown to be involved in EMT of PCa, the role of miR-363 has not been reported. This miR-363 belongs to the miR-106a-363 cluster containing additional miRNAs such as106a, 18b, 20b, 19b-2, and 92a-2, which are closely resemble to the oncogenic miR-17-92 cluster characterized as an oncomir. However, no miR-363 homolog is found in this cluster and also its functional role is largely unknown. In addition, the regulation of miRNA expression becomes more complicated when a polycistronic primary transcript from a miRNA gene cluster generates each individual miRNA with different expression profile and functional role. In this study, we have unveiled a new protein complex responsible for the specific miR-363 turnover.

Methods: RNA pull down assay, immunoprecipitation assay, Liquid chromatography-tandem mass spectrometry, and in vitro RNA degradation assay were for determining miR-363 turnover. Real-time RT-PCR, luciferase reporter gene and cell invasion assays were for determining the function and mechanism of miR-363.

Results: Unlike other members characterized as oncomirs from the same cluster, miR-363 functions as an inhibitor of EMT by targeting Slug in PCa cells. Also, a dramatic down-regulation of mature miR-363 is found in PCa cells exhibiting EMT phenotypes, which is mediated by pre-miR-363 degradation. We further identify interferon-induced tetratricopeptide repeat 5 (IFIT5) as a key factor in mediating miR-363 turnover; which is also highly elevated in PCa tissues with high-grade tumor. IFIT5 is first characterized as a viral RNA binding protein, until now, there is no report indicating the role of IFIT5 in miRNA turnover. Nevertheless, IFIT5 was further characterized to unveil that it can recognize a unique structure at the 5'-end of pre-miR-363, which facilitates pre-miR-363 degradation by recruiting a 5'-3’exoribonuclease (i.e., XRN1). This regulation appears to be structure specific because IFIT5 fails to bind to other miRNAs from the same cluster to elicit their turnover. We also notice that IFIT5 can accelerate the turnover of miRNAs with the similar 5’-end structure of pre-miR-363. Meanwhile, the significant elevation of IFIT5 is detected in several PCa cell lines undergone EMT leading to highly metastatic potential. In addition, an inverse correlation between miR-363 and IFIT5 mRNA level was also found in PCa specimens.

Conclusion: miR-363 is a potent anti-EMT miRNA in PCa. IFIT5 complex represents unique post-transcriptional machinery for miR-363 turnover, which provide a new model of miRNA regulation from a cluster of miRNAs with different functions. Overall, this study provides a new insight of miRNA biogenesis machinery in cancer metastasis and potential new therapeutic target for mCRPC.